Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer
Phase: PHASE2
Conditions: Triple Negative Breast Cancer
Sponsor: Duke University

 
 
 
Drug Substance 
Olaparib (AZD2281, KU-0059436), Durvalumab (MEDI 4736) 
Study Number 
 ESR-15-11311/EPM 6724 
Version Number 
6.0 
Date 
14Jun2021 
 
NCT03167619 
 
PHASE II MULTICENTER STUDY OF DURVALUMAB 
(MEDI4736) AND OLAPARIB IN PLATINUM TREATED 
ADVANCED TRIPLE NEGATIVE BREAST CANCER - DORA 
 
 
STUDY CHAIRS 
Dr. Rebecca A. Dent 
 
Senior Consultant 
National Cancer Center Singapore 
rebecca.dent@duke-nus.edu.sg 
 
 
Dr. Sarah Sammons 
 
Duke Cancer Institute 
 
Duke University Medical Center 
 
Sarah.Sammons@duke.edu 
 
 
 
 
 
 
CORRELATIVE SCIENCE CHAIR 
Dr. Tira J. Tan 
 
Consultant 
 
National Cancer Center Singapore 
 
Tira.Tan@uhn.ca 
 
 
DCRI PROJECT LEADER 
Kelly Mundy 
 
Duke Clinical Research Institute 
 
kelly.mundy@duke.edu 
 
 
 
 
 
 
 
 
 
1(80) 

Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
2(80) 
 
 
 
 
 
TABLE OF CONTENTS 
PAGE 
 
 
TABLE OF CONTENTS............................................................................................................................. 2 
 
LIST OF TABLES .............................................................................................................................. 5 
 
LIST OF FIGURES............................................................................................................................. 5 
 
1 
Re: IND 133602 / A0005 • DORA.................................................................................................... 6 
 
2 
Daniel K. Benjamin, MD, MPH, PhD ............................................................................................... 7 
 
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS ............................................................. 8 
 
1 
Introduction ................................................................................................................................ 13 
1.1 
Drug efficacy, safety and dosing: background ...................................................................................14 
1.1.1 
Olaparib in the context of breast cancer ............................................................................................... 14 
1.1.2 
Preclinical experience with olaparib ...................................................................................................... 15 
1.1.3 
Toxicology and safety pharmacology summary for olaparib ................................................................. 15 
1.1.4 
Clinical experience with olaparib ........................................................................................................... 15 
1.1.5 
Clinical experience with durvalumab ..................................................................................................... 18 
1.2 
Research hypothesis ........................................................................................................................18 
1.3 
Rationale for conducting this study ..................................................................................................18 
1.4 
Benefit/risk and ethical assessment .................................................................................................19 
1.5 
Rationale for drug dosing in this study..............................................................................................20 
1.5.1 
Rationale for dose of olaparib................................................................................................................ 20 
1.5.2 
Rationale for Durvalumab fixed dosing.................................................................................................. 20 
1.5.3 
Rationale for dose of olaparib in combination with durvalumab .......................................................... 21 
2 
Study Objectives ......................................................................................................................... 22 
2.1 
Primary objective.............................................................................................................................22 
2.2 
Secondary objectives .......................................................................................................................22 
2.3 
Exploratory objectives......................................................................................................................22 
 
3 
Study design ............................................................................................................................... 24 
3.1 
Overall study structure and flow chart..............................................................................................24 
3.2 
Rationale for study design, doses and control groups........................................................................25 
3.3 
Rationale for prior treatment with platinum.....................................................................................25 
3.4 
Inclusion Criteria..............................................................................................................................26 
3.5 
Exclusion Criteria .............................................................................................................................28 
3.6 
Restrictions during the study ............................................................................................................30 
3.6.1 
Pregnancy/Breastfeeding....................................................................................................................... 30 
3.6.2 
Surgery ................................................................................................................................................... 32 
3.6.3 
Radiation ................................................................................................................................................ 33 
3.6.4 
Administration of other anti-cancer agents........................................................................................... 33 
3.6.5 
Blood donation....................................................................................................................................... 33 
3.6.6 
Other concomitant treatment and medications.................................................................................... 33 
3.7 
Data Management ...........................................................................................................................34 
3.8 
Evaluation and calculation of variables .............................................................................................35 
3.9 
Calculation or derivation of efficacy variable(s).................................................................................35 

Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
3(80) 
 
 
 
3.9.1 
Evaluation of Best Overall Response...................................................................................................... 36 
 
4 
Stud y procedures and assessments ............................................................................................. 36 
4.1 
Subject enrollment and randomization .............................................................................................36 
4.1.1 
Informed consent ................................................................................................................................... 36 
4.1.2 
Screening Procedures............................................................................................................................. 37 
4.1.5 Post-platinum chemotherapy tumor evaluation...................................................................................... 38 
4.1.6 
Procedures for randomization............................................................................................................... 39 
4.1.7 
Procedures for handling ineligible or screen-fail subjects ..................................................................... 39 
4.2 
Treatments ......................................................................................................................................39 
4.2.1 
Identity of investigational product(s)..................................................................................................... 39 
4.2.2 
Olaparib .................................................................................................................................................. 40 
4.2.3 
Olaparib: doses and treatment regimens .............................................................................................. 40 
4.2.4 
Management of toxicity of olaparib ...................................................................................................... 40 
4.2.5 
Durvalumab ............................................................................................................................................ 44 
4.2.6 
Durvalumab: drug preparation .............................................................................................................. 44 
4.2.7 
Durvalumab: Doses and treatment regimens ........................................................................................ 45 
4.2.8 
Durvalumab: monitoring of dose administration .................................................................................. 46 
4.2.9 
Management of toxicity of durvalumab ................................................................................................ 47 
4.2.10 
Labeling .............................................................................................................................................. 49 
4.2.11 
Storage ............................................................................................................................................... 49 
4.2.12 
Treatment compliance....................................................................................................................... 49 
4.2.13 
Accountability .................................................................................................................................... 50 
4.3 
Discontinuation of study treatment ..................................................................................................51 
4.4 
Procedures for discontinuation of a subject from investigational product..........................................52 
4.5 
Collection of study variables.............................................................................................................52 
4.5.1 
During olaparib or olaparib and durvalumab maintenance................................................................... 52 
4.5.2 
Subsequent visits.................................................................................................................................... 53 
4.5.3 
End-of-study visit ................................................................................................................................... 54 
4.6 
Biological sampling procedures ........................................................................................................55 
4.6.1 
Handling, storage and destruction of biological samples ...................................................................... 56 
4.6.2 
Biomarker samples................................................................................................................................. 56 
4.6.3 
Withdrawal of informed consent for donated biomarker samples ....................................................... 56 
4.7 
Follow-up procedures ......................................................................................................................56 
4.8 
Efficacy ............................................................................................................................................57 
4.8.1 
Efficacy outcome measures ................................................................................................................... 57 
 
5 
S afety ......................................................................................................................................... 60 
5.1 
Definition of adverse events.............................................................................................................60 
5.2 
Definitions of serious adverse event .................................................................................................60 
5.3 
Definition of adverse events of special interest (AESI) .......................................................................61 
5.4 
Recording of adverse events.............................................................................................................61 
5.4.1 
Time period for collection of adverse events and serious adverse events............................................ 63 
5.5 
Follow-up of unresolved adverse events ...........................................................................................63 
5.6 
Adverse events based on signs and symptoms ..................................................................................63 
5.7 
Adverse events based on examinations and tests .............................................................................63 
5.8 
Disease progression .........................................................................................................................64 
5.9 
New cancers ....................................................................................................................................64 
5.10 
Lack of efficacy ................................................................................................................................64 

Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
4(80) 
 
 
 
5.11 
Deaths .............................................................................................................................................64 
5.12 
Other events requiring reporting ......................................................................................................64 
5.12.1 
Pregnancy .......................................................................................................................................... 64 
5.12.5 
Reporting of serious adverse events ................................................................................................. 65 
6 
Ethical and regulatory requirements............................................................................................ 66 
6.1 
Ethical conduct of the study .............................................................................................................66 
6.2 
Subject data protection....................................................................................................................67 
6.3 
Ethics and regulatory review ............................................................................................................67 
6.4 
Informed consent ............................................................................................................................67 
6.5 
Changes to the protocol and informed consent form ........................................................................67 
6.6 
Protocol deviations ..........................................................................................................................68 
6.7 
Publication policy.............................................................................................................................68 
7 
Statistical Methods and sample size determination ..................................................................... 68 
7.1 
Statistical analyses and determination of sample size .......................................................................68 
7.2 
Safety data review committee..........................................................................................................68 
 
8 
LIST OF REFERENCES .................................................................................................................... 69 
 
9 
APPENDICES ................................................................................................................................ 72 
 
Appendix A : Schedule of Assessments................................................................................................ 72 
 
Appendix B : Known Strong in Vivo Inhibitors or Inducers of CYP3A .................................................... 75 
 
Appendix C : Adverse Event Assessment of Causality .......................................................................... 76 
 
Appendix D : Under 30 kg Total Body Weight Durvalumab Dose calculation ........................................ 77 
 
Appendix E : Assessment of Possible Drug Induced Liver Injury ........................................................... 78 
 
Appendix F : Toxicity Management Guidelines (Version – 17Oct2019) ................................................. 79 
 
Appendix G : Additional required tests (Korean sites ONLY) .............................................................. 80 

Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
5(80) 
 
 
 
 
LIST OF TABLES 
 
 
 
Table 1: Highly Effectivea Methods of Contraception  
31 
Table 2: Identity of Investigational Product  
41 
Table 3: Durvalumab hold and infusion times   
47 
Table 4: Durvalumab dose modification due to toxicity   
48 
Table 5: Management of immune-related adverse events   
49 
Table 6. Hematology Laboratory Tests   
55 
Table 7. Clinical chemistry (Serum or Plasma) Laboratory Tests   
56 
Table 8: Volume of blood to be drawn from each subject   
57 
Table 9: Response criteria   
58 
Table 10: Definition of best overall response as per RECIST criteria   
60 
 
 
 
 
 
 
LIST OF FIGURES 
 
 
 
Figure 1: Study Schema   
24 

Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
6(80) 
 
 
 
 
 
 
July 02, 2018 
 
Food and Drug Administration 
 
Center for Drug Evaluation and Research Division 
of Cardiovascular and Renal Products 5901-B 
Ammendale Road 
 
Beltsville, MD 20705-1266 
 
Attn: Kim Robertson 
 
 
 
1 RE: IND 133602 / A0005 • DORA 
 
General Correspondence: Transfer of IND Sponsor 
 
 
 
 
Dear Sir/Madam, 
 
 
 
 
Phase II Multicenter Study of Durvalumab and Olaparib in Platinum treated advanced triple negative 
breast cancer – DORA is being conducted under the above referenced IND. This is a prospective, 
randomized, multi-center, safety and efficacy study. No sites have been activated, and no participants 
have enrolled to the study yet. Study enrollment is expected to begin later this year (estimate August 
1st, 2018). The investigational plan is to activate a total of 6 sites (3 US, 2 Korea, 1 Singapore) under 
this IND. 
 
 
 
 
This is to inform you that, effective July 02, 2018, I, Dr. Danny Benjamin, MD, have transferred all 
rights for IND 133602 to Dr. Sarah Sammons, MD of Duke University. Dr. Sammons will receive a 
complete record of the IND. 
 
 
 
 
Sincerely, 
 
 
 
 
Danny 
Benjamin, MD 
PhD 

Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
7(80) 
 
 
 
 
 
2 DANIEL K. BENJAMIN, MD, MPH, PHD 
 
Kiser-Arena Distinguished Professor of Pediatrics, 
Duke University Faculty Associate Director, Duke 
Clinical Research Institute 
 
300 W. 
Morgan 
Street 
Durham, 
NC 
27701 
 
Ph 919-668-8295 
 
Fax 919-681-9457 
 
Email: danny.benjamin@duke.edu 

Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
8(80) 
 
 
 
 
 
 
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS 
The following abbreviations and special terms used in the Clinical Study Protocol. 
(Page left intentionally blank) 

Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
9(80) 
 
 
 
 
 
Abbreviation or 
Special term 
Explanation 
 
AE 
adverse event 
 
AESI 
adverse event of special interest 
 
ALP 
alkaline phosphatase 
 
ALT 
alanine transaminase 
 
APTT 
activated partial thromboplastin time 
 
AST 
aspartate transaminase 
bid 
twice daily 
BMI 
body mass index 
 
BP 
blood pressure 
 
BUN 
blood urea nitrogen 
 
CFR 
Code of Federal Regulations 
 
CR 
complete response 
 
CT 
computerized tomography 
 
CTCAE 
common terminology criteria for adverse events 
 
DCI 
Duke Cancer Institute 
 
DCO 
data cut-off 
 
DCRI 
Duke Clinical Research Institute 
 
DNA 
deoxy-ribonucleic acid 
DSB 
double strand breaks 
EC 
European Commission 
ECG 
Electrocardiogram 
eCRF 
electronic case report form 
 
EOT 
end of treatment 
 
ER 
estrogen receptor 
 
FDA 
Food and Drug Administration 
 
G-CSF 
granulocyte colony-stimulating factor 
 
GGT 
gamma glutamyltransferase 
 
Hb 
Hemoglobin 
 
Hct 
Hematocrit 

Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
10(80) 
 
 
 
 
 
HDPE 
high density polyethylene 
 
HER2 
human epidermal growth factor receptor 2 
 
HIV 
human immunodeficiency virus 
HR 
homologous recombination repair 
HRD 
HR deficiency 
IB 
investigator’s brochure 
 
ICF 
informed consent form 
 
ICH 
International Conference on Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for Human Use 
 
IEC 
Institutional Ethics Committee 
 
Ig 
Immunoglobulin 
 
IHC 
Immunohistochemistry 
 
IND 
investigational new drug 
 
INR 
international normalized ratio 
 
IP 
Investigational Product 
 
irAEs 
immune-related adverse events 
 
IRB 
Institutional Review Board 
 
iRECIST 
RECIST adapted for response with immunotherapeutics 
 
IV 
Intravenous 
 
LD 
longest diameter 
 
LSD 
lysine-specific histone demethylase 
 
MCH 
mean cell hemoglobin 
 
MCHC 
mean cell hemoglobin concentration 
 
MCV 
mean cell volume 
 
MDS 
myelodysplastic syndrome 
 
MedDRA 
medical dictionary for regulatory activities 
 
MRI 
magnetic resonance imaging 
 
mTNBC 
metastatic triple negative breast cancer 
 
NCI 
National Cancer Institute 
 
OAEs 
other significant adverse events 
od 
once daily 

11(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
OS 
overall survival 
 
PARP 
poly (adenosine diphosphate ribose) polymerases 
 
PD 
progressive disease 
 
PD-L1 
programmed death ligand-1 
 
PFS 
progression free survival 
 
PK 
pharmacokinetics 
PR 
partial response 
Q2W 
dose every 2 weeks 
Q4W 
dose every 4 weeks 
RBC 
red blood cells 
RECIST 
Response Evaluation Criteria in Solid Tumors 
 
RI 
reticulocyte Index 
 
RP2D 
recommended phase 2 dose 
 
SAE 
serious adverse event 
 
SD 
stable disease 
 
SGGCP 
Singapore Guideline for Good Clinical Practice 
 
SSBs 
single strand breaks 
 
TILs 
tumor-infiltrating lymphocytes 
TNBC 
triple negative breast cancer 
ULN 
upper limit of normal 
WBC 
white blood cells 
 
WT 
Weight 

12(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
PROTOCOL APPROVAL PAGE 
 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated 
Advanced triple negative breast cancer – DORA 
 
 
Protocol Number: ESR-15-11311/EPM 6724 
Protocol Version/ Date: V 6.0, 14Jun2021 
 
Declaration of Investigator 
 
I confirm that I have read the above-mentioned protocol and its attachments. I agree to conduct 
the described trial in compliance with all stipulations of the protocol, regulations and in 
accordance with Good Clinical Practice (GCP). 
 
I confirm that I have read the protocol and its attachments. I agree to conduct the described 
trial in compliance with 
 
• This protocol, ESR-15-11311/EPM 6724, 
• Good Clinical Practice guidelines (eg, ICH E6: Good Clinical Practice), 
• Applicable regulatory requirements from the United States Code of Federal 
Regulations including 21 CFR parts 312 (Investigational New Drug [IND]), 50 
(Protection of Human Subjects), 56 (institutional review board [IRB]), and 11 
(electronic records and signatures). 
• Country-specific regulatory requirements 
 
 
 
 
 
Study Site Principal Investigator Name:                                                                                      
 
 
 
 
Study Site Principal Investigator Signature:   
 
 
 
 
 
Date:    
 

13(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
1    INTRODUCTION 
 
Ten to twenty percent of invasive breast tumors are negative for all three predictive and 
prognostic immunohistochemical biomarkers—estrogen receptor (ER), progesterone receptor 
and human epidermal growth factor receptor 2 (HER2); these cancers are known collectively as 
triple negative breast cancer (TNBC).1  Women with TNBC have an increased likelihood of 
distant recurrence and death as compared with women with other types of breast cancer.2 
 
Breast cancer in the advanced stage remains an incurable disease, with general goals of therapy 
being to prolong survival, palliate symptoms, and optimize quality of life. In this disease setting, 
continuation of first-line chemotherapy results in a significantly improved overall survival 
(OS).3 Whereas maintenance chemotherapy is desirable to prolong tumor responses, toxicities 
often limit its continuation. 
 
The role of maintenance olaparib, a poly (adenosine diphosphate ribose) polymerase (PARP) 
inhibitor, has been explored in platinum-sensitive relapsed ovarian cancer; the median 
progression-free survival (PFS) and OS in subjects with Breast Cancer (BRCA) gene mutation 
on maintenance olaparib was significantly longer than that in the placebo group, with a tolerable 
toxicity profile.4, 5 A significant proportion of TNBCs arise in BRCA mutation carriers6, 7 and / 
or have gene expression profiles (basal-like) similar to that of BRCA-deficient tumors.8 The 
therapeutic implication of this lies in exploiting synthetic lethality, resulting in disease control 
with favorable toxicity profile similar to that described in ovarian cancer. 
 
The immune system can identify tumor-associated antigens and eliminate the cancerous cells 
expressing them; thus it plays an important role in combating tumor growth. However, tumor 
cells with reduced immunogenicity or an enhanced immunosuppressive mechanism contribute 
to the failure of the immune system in controlling tumor growth. Several factors may contribute 
to this failure, including expression of immune-inhibitory molecules, presence of 
immunosuppressive-regulatory T lymphocytes or immunosuppressive cytokines within the 
tumor microenvironment, and down-regulation of major histocompatibility molecules and 
tumor antigens leading to reduced antigen presentation and recognition. 
 
The programmed death ligand-1 (PD-L1) is part of a complex system of receptors and ligands 
that are involved in control of T cell activation. In normal tissues, PD-L1 is expressed on T cells, 
B cells, dendritic cells, macrophages, and mesenchymal stem cells, as well in as a variety of 
non-hematopoietic cells. The normal function of PD-L1 is to regulate the balance between T 
cell activation and tolerance. Also expressed by tumors, PD-L1 acts at multiple sites; thereby, 
tumors evade detection and elimination by the host immune system. In the tumor 
microenvironment, PD-L1 expressed on tumor cells binds to PD-1 on activated T cells reaching 
the tumor. This delivers an inhibitory signal to those T cells, preventing them from killing the 
target tumor cells and thus protecting the tumor from the immune system. 
 
Recent studies have demonstrated high levels of tumor-infiltrating lymphocytes (TILs) in 
hormone-receptor negative and high grade tumors such as that of TNBC9,10,11,12 as compared 
with hormone-receptor positive tumors. Increased levels of TILS has been associated with 
higher expression of PD-L1 messenger ribonucleic acid (mRNA)13, which is significantly 

14(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
higher in TNBC compared with non-TNBC.14 This in turn has been correlated with improved 
prognosis in a number of cancers, suggestive of an important anti-tumor immune response. An 
anti-PD-L1 antibody could thus be used therapeutically to enhance anti-tumor immune 
responses in subjects with cancer. In addition, combining therapies with distinct, and potentially 
complementary, mechanisms of actions may further enhance the anti-tumor efficacy of each 
individual treatment. 
 
In the context of advanced TNBC, the combination of PARP inhibition and PD-1 immune 
checkpoint inhibition is a therapeutic strategy worthy of further investigation. 
 
Preclinical data (unpublished) suggests that those triple negative cell lines that are responsive 
to platinum chemotherapy are more likely to respond to the PARP inhibitor, olaparib. We 
hypothesize that olaparib either alone or in combination with the PD-L1 inhibitor will be 
efficacious in TNBC subjects who have responded to platinum-based chemotherapy. 
 
1.1    Drug efficacy, safety and dosing: background 
 
1.1.1    Olaparib in the context of breast cancer 
 
Olaparib (AZD2281, KU-0059436) is a potent PARP inhibitor (PARP-1, -2 and -3) that has 
been approved as a monotherapy for treating patients with BRCA mutated advanced ovarian 
cancer following three or more prior lines of chemotherapy, it is also being developed both as a 
monotherapy (including maintenance) and for combination with chemotherapy and other anti- 
cancer agents. It is approved for use by both the European Commission (EC) and the U.S. Food 
and Drug Administration (FDA) in the treatment of women with BRCA-mutated advanced 
ovarian cancer. In January 2018, the FDA granted approval to olaparib tablets for the treatment 
of patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative 
metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, 
adjuvant or metastatic setting. This is based on data from OlympiAD, an open-label randomised 
phase III study investigating olaparib vs. physician’s choice of chemotherapy (capecitabine, 
vinorelbine or eribulin) in patients with germline BRCA mutated, HER2 negative metastatic 
breast cancer. 
 
Poly (adenosine diphosphate ribose) polymerase (PARP) inhibition is a novel approach that 
targets tumors with deficiencies in deoxyribonucleic acid (DNA) repair mechanisms. PARP 
enzymes are essential for repairing DNA single-strand breaks (SSBs). Inhibiting PARPs leads 
to the persistence of SSBs, which are then converted to the more serious DNA double-strand 
breaks (DSBs) during the process of DNA replication. During the process of cell division, DSBs 
can be efficiently repaired in normal cells by homologous recombination repair (HR). Tumors 
with HR deficiencies (HRD), such as serous ovarian cancers and BRCA1 and BRCA2 breast 
cancers15,16,17 cannot accurately repair the DNA damage, which may become lethal to cells as it 
accumulates. In such tumor types, olaparib may offer a potentially efficacious and less toxic 
cancer treatment compared with currently available chemotherapy regimens. 
 
Olaparib has been shown to inhibit selected tumor cell lines in vitro and in xenograft and primary 
explant models, as well as in genetic BRCA knock-out models, either as a stand-alone treatment 
or in combination with established chemotherapies. Cells deficient in homologous 

15(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
recombination DNA repair factors, notably BRCA1/2, are particularly sensitive to olaparib 
treatment. 
 
PARP inhibitors such as olaparib may also enhance the DNA-damaging effects of 
chemotherapy.16,18,19 For further information, please refer to the current version of the olaparib 
IB. 
 
1.1.2    Preclinical experience with olaparib 
 
Initial in vitro studies have identified olaparib as an effective agent in potentiating cell-killing 
by the alkylating agent methyl methanesulfonate11. Direct measurement of PARP-1 inhibitory 
activity in SW620 cell lysates identified the IC50 for PARP-1 inhibition to be around 6 nm, with 
total ablation of PARP-1 activity to be at concentrations of 30–100 nM.11 The ability of olaparib 
to potentiate antitumor activity of temozolomide was further evaluated in vivo in animals 
bearing SW620-xenografted tumors. There was clear potentiation of temozolomide activity by 
olaparib, which was well tolerated when administered in combination.11 Furthermore, cell lines 
that are deficient in homologous recombination as a result of non-functional BRCA1 or BRCA2 
have been shown to be profoundly sensitive to PARP inhibition.3,12 
 
 
1.1.3    Toxicology and safety pharmacology summary for olaparib 
 
Olaparib has been tested in a standard range of safety pharmacology studies, eg, dog 
cardiovascular and respiratory function tests, and the rat Irwin test. There were no noticeable 
effects on the cardiovascular or respiratory parameters in the anaesthetized dog or any 
behavioral, autonomic, or motor effects in the rats at the doses studied.20 
 
Toxicology studies indicate that the bone marrow is the target organ of toxicity. In toxicity 
studies up to 6 months in rats and dogs, any changes in hematology parameters were fully or 
partially resolved upon withdrawal of the drug. Olaparib was found to have some mutagenic 
effects in rats that were to be expected given its primary target. There were no reproductive 
adverse effects in male rats, but fetal survival was decreased and fetal malformations increased, 
again to be expected given the primary pharmacology of olaparib. 
 
Further information can be found in the current version of the olaparib Investigator’s Brochure 
(IB). 
 
1.1.4     Clinical experience with olaparib 
 
Clinical experience with olaparib is fully described in the current version of the olaparib 
Investigator’s Brochure. 
 
The capsule formulation of olaparib was approved in December 2014 by the European 
commission (EC) for the indication: monotherapy for the maintenance treatment of adult 
patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high 
grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in 
response to platinum-based chemotherapy. The United States (US) Food and Drug 
Administration (FDA) has approved olaparib capsules as monotherapy in patients with 

16(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA 
approved test) advanced ovarian cancer who have been treated with three or more prior lines 
of chemotherapy. The tablet formulation was registered for use in the US in 
August 2017 for ovarian cancer and in January 2018 for breast cancer. All ongoing studies, 
including the Phase III registration studies, are being performed with the tablet formulation. 
and the majority of patients treated with olaparib in AstraZeneca-sponsored clinical studies 
have received the tablet formulation. 
 
As of 15 December 2018, approximately 10682 patients are estimated to have received 
olaparib in clinical programmes, investigator sponsored studies and collaborative group 
studies. An estimated 6956 subjects with ovarian, breast, gastric, pancreatic, and a variety of 
other solid tumors are estimated to have received treatment with olaparib across the dose range 
10 mg once daily to 600 mg twice daily (bid) in AstraZeneca-sponsored, investigator- 
sponsored, and collaborative group studies. Olaparib has been given as either monotherapy or 
in combination with other chemotherapy/anti-cancer agents. Since 2012/2013, most new 
clinical studies have utilized the tablet formulation, which was designed to deliver the 
therapeutic dose of olaparib in fewer dose units than the capsule. Of the 6108 patients in 
AstraZeneca-sponsored, interventional studies,1567 received the capsule formulation, 4516 
received the tablet formulation, and 25 received both capsule and tablet. 
 
The tablet formulation of olaparib (2 tablets bid) is considered much more subject-friendly; 
the tablet dose of 300 mg bid has been shown to demonstrate similar efficacy in terms of 
tumor shrinkage in BRCA-mutated ovarian cancer subjects as compared with the 400 mg bid 
capsule formulation—together with an acceptable safety profile. 
 
 
 
The regulatory approval status of the tablet formulation of olaparib is as follows: 
 
US: Approved in August 2017 for maintenance treatment of adult patients with recurrent 
epithelial ovarian, fallopian tube or primary peritoneal cancer following response to platinum- 
based chemotherapy; and for the treatment of adult patients with deleterious or suspected 
deleterious germline BRCA mutated advanced ovarian cancer who have been treated with 3 or 
more prior lines of chemotherapy. Approved in January 2018 for patients with deleterious or 
suspected deleterious germline BRCA mutated HER2 negative metastatic breast cancer who 
have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic 
setting.  Patients with hormone receptor positive breast cancer should have been treated with a 
prior endocrine therapy or be considered inappropriate for endocrine treatment. 
 
EU indication: Approved in May 2018 as monotherapy for the maintenance treatment of 
adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube 
or primary peritoneal cancer who are in response (complete or partial) to platinum-based 
chemotherapy. 
 
Japan: Approved in January 2018 as maintenance treatment for adult patients with recurrent 
ovarian cancer who are sensitive to platinum based chemotherapy. 

17(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
Emerging safety profile indicate that olaparib is generally well tolerated at monotherapy doses 
up to 400 mg bid (capsule formulation) and 300 mg bid (tablet formulation) in subjects with 
solid tumors. Administration of olaparib monotherapy has been associated with reports of 
laboratory findings and/or clinical diagnoses of: 
 
• Hematological toxicity: 
• Anemia, (very common and of all CTCAE grades) 
• Neutropenia (common) 
• Lymphopenia (uncommon) 
• Thrombocytopenia (common) 
• Mean corpuscular volume elevation 
• Increased creatinine, generally mild or moderate intensity (CTCAE Grade 1 or 2) 
• Nausea and vomiting, generally mild or moderate (CTCAE Grade 1 or 2), intermittent 
and manageable on continued treatment 
• Stomatitis, generally mild or moderate (CTCAE Grad 1 or 2) 
• Decreased appetite, generally mild or moderate intensity (CTCAE Grade 1 or 2) 
• Diarrhea, generally mild or moderate intensity (CTCAE Grade 1 or 2) 
• Dyspepsia and upper abdominal pain, generally mild or moderate intensity (CTCAE 
Grade 1 or 2) 
• Dysgeusia, generally mild or moderate intensity (CTCAE Grade 1 or 2) 
• Dyspnea, very common, (CTCAE all grades) 
• Fatigue (including asthenia), generally mild or moderate intensity (CTCAE Grade 1 or 
2) 
• Headache, generally mild or moderate intensity (CTCAE Grade 1 or 2) 
• Dizziness, generally mild or moderate intensity (CTCAE Grade 1 or 2) 
• Cough, generally mild or moderate intensity (CTCAE Grade 1 or 2 
 
Myelodysplastic syndrome (MDS) and acute myeloid leukemia have been reported in <1% of 
subjects. The cases were typical of secondary MDS or therapy related acute myeloid leukemia. 
The duration of therapy with olaparib in subjects who developed secondary MDS or acute 
myeloid leukemia varied from <6 months to >2 years. All subjects had potential contributing 
factors for the development of MDS/acute myeloid leukemia, having received extensive 
previous chemotherapy with platinum agents. Many had also received other DNA-damaging 
agents. 
 
New primary malignancies have been reported in a small number of subjects. There were other 
contributing factors or potential alternative explanations for the development of the new primary 
malignancy in all cases. 
 
Pneumonitis events have been reported in <1% of subjects receiving olaparib. The reports of 
pneumonitis had no consistent clinical pattern and were confounded by a number of 
predisposing factors (cancer and/or metastases in lungs, underlying pulmonary disease, smoking 
history, and/or previous chemotherapy and radiotherapy). 

18(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
1.1.5    Clinical experience with durvalumab 
 
Durvalumab is an investigational human monoclonal antibody of the immunoglobulin (Ig) G1 
kappa subclass that inhibits binding of PD-L1 to PD-1 and CD80. 
 
As of the Data cut-off (DCO) dates (12 July 2018), a total of 5127 subjects have been enrolled 
and treated in ongoing durvalumab clinical studies. Of these, 2229 patients received durvalumab 
monotherapy, 1573 patients received durvalumab in combination with tremelimumab, and 1325 
patients received durvalumab in combination with an investigational and or an approved 
product. No studies have been completed or terminated prematurely due to toxicity. 
 
Durvalumab has been given in ongoing studies as monotherapy or in combination with other 
drugs. The majority of safety data is based on the first-in-human single agent study in subjects 
with advanced solid tumors (Study 1108). Durvalumab was given intravenous (IV) every 2 or 
3 weeks in a 3+3 dose escalation followed by expansion in 8 solid tumor types, one of which 
being TNBC. In the expansion cohort, durvalumab was given at a dose of 10 mg/kg IV every 
2 weeks. Overall, the most frequently reported adverse events (AEs) were fatigue, nausea, 
dyspnea, decreased appetite, constipation, diarrhea, vomiting, cough, pyrexia, back pain, and 
rash. Approximately half of these AEs were Grade 1 to 2 in severity and manageable by general 
treatment guidelines. Grade 3 or higher AEs were noted in 35.9%. The events occurring in more 
than 1% of subjects were dyspnea (5.1%), increased gamma-glutamyltransferase (3.3%); 
fatigue, general physical health deterioration, increased aspartate aminotransferase, and back 
pain (2.3% each); anemia and dehydration (1.8% each); and abdominal pain vomiting, sepsis, 
syncope, and hypotension (1.3% each). No dose-limiting toxicities have been reported. 
 
Efficacy data on durvalumab monotherapy in the expansion cohort was presented at American 
Society of Clinical Oncology (ASCO) 2014. With a median follow-up of 6 weeks, tumor 
shrinkage has already been seen in multiple tumor types. Durable responses have also been 
observed; this supports further development of durvalumab. Clinical assessments and subject 
enrollment are ongoing. 
 
1.2    Research hypothesis 
 
Preclinical data (unpublished) suggests that triple negative cell lines that are responsive to 
platinum chemotherapy are more likely to respond to the PARP inhibitor, olaparib. In the 
context of advanced TNBC, the combination of PARP inhibition and PD-1 immune checkpoint 
inhibition is a therapeutic strategy worthy of further investigation. We hypothesize that olaparib 
either alone or in combination with the PD-L1 inhibitor, durvalumab may be efficacious in 
TNBC patients who have responded to platinum-based therapy. 
 
1.3    Rationale for conducting this study 
 
Women with TNBC do not respond to estrogen/progesterone based endocrine therapy or other 
available targeted agents.  Chemotherapy remains the mainstay of treatment. In the metastatic 
setting, these tumors are associated with a shorter median time to relapse and death compared 
to other metastatic breast cancer subtypes.21  With the poorest prognosis of all breast cancer 
subtypes, this disease represents an important challenge and remains an unmet clinical need. 

19(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
Over the last 5 years, potential targeted strategies for molecular subtypes of TNBC have been 
identified. A significant proportion of TNBCs (~30%) arises in BRCA gene mutation carriers 
or have gene expression profiles similar to BRCA deficient tumors representing a defective 
DNA damage repair system.22,23 The therapeutic implication of this susceptibility has led to the 
development of synthetic lethality strategies such as treatment with polyADP-ribose 
polymerases (PARP) inhibitors such as olaparib.   Furthermore, pathological studies have 
reported predictive and prognostic roles for the presence of TILs in hormone receptor negative 
and high-grade tumors such as advanced TNBC.24,25  Consistent with these findings, multiple 
transcriptomic studies have identified TNBC subtypes characterized by altered expression of 
immune-response genes.23 Several hypotheses for persistent disease despite chemotherapy and 
an active immune system response have been proposed, including masking of malignant cells 
by a variety of mechanisms, chronic antigen exposure, and “T cell exhaustion”. A series of new 
immune-based therapies in which disruption of malignant cell masking by inhibition of CTLA- 
4 or PD-1/PD-L1 axes have entered the clinic. These have been studied in the context of several 
Phase 1 studies, which have reported significant promising clinical activity.26,27,28 This clinical 
protocol assesses the activity of olaparib as well as the combination of olaparib and PD-L1 
immunotherapy where two therapies with distinct and potentially complementary mechanisms 
of actions may further enhance anti-tumor efficacy. 
 
1.4    Benefit/risk and ethical assessment 
 
Data from the available pre-clinical studies and subsequent clinical development program 
demonstrate that olaparib appears to be active and generally well tolerated in subjects with solid 
tumors, including those with BRCA-mutated cancers. In ovarian cancer, responses have been 
seen in all subject groups, including platinum-resistant and refractory cancer. 
 
From available studies, there is no evidence of any unexpected toxicity following long-term 
olaparib (capsule) monotherapy exposure in subjects with advanced cancer. 
 
Adverse laboratory findings and/or clinical diagnoses considered to be associated with 
administration of olaparib monotherapy include hematological effects (anemia, neutropenia, 
lymphopenia, thrombocytopenia, MCV elevation and increase in blood creatinine), nausea and 
vomiting, decreased appetite, diarrhea, dyspepsia, stomatitis, upper abdominal pain, dysgeusia, 
fatigue (including asthenia), headache, dyspnea and dizziness. Most of these events were 
generally mild or moderate in intensity. 
 
In a small number of subjects, pneumonitis, MDS/AML, and new primary malignancies have 
been observed. Evidence from across the development program for olaparib does not support a 
conclusion that there is a causal relationship between olaparib and these events. These are 
important potential risks for olaparib and are being kept under close pharmacosurveillance. 
 
Identified risks with durvalumab are diarrhea, increases in transaminases, pneumonitis and 
colitis. 
 
Potential risks include endocrinopathies (hypo- and hyper-thyroidism, hypophysitis and adrenal 
insufficiency),    development    of    type    1    diabetes    mellitus,    hepatitis/hepatotoxicity, 

20(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
neurotoxicities, nephritis, pancreatitis, dermatitis, infusion-related reactions, anaphylaxis, 
hypersensitivity or allergic reactions, and immune complex disease. Further information on 
these risks can be found in the current version of the durvalumab IB. 
 
1.5    Rationale for drug dosing in this study 
 
1.5.1    Rationale for dose of olaparib 
 
As of 15 December 2018, approximately 10682 patients are estimated to have received olaparib 
in clinical programmes, investigator sponsored studies and collaborative group studies. An 
estimated 6956 subjects with ovarian, breast, gastric, pancreatic, and a variety of other solid 
tumors are estimated to have received treatment with olaparib across the dose range 10 mg once 
daily to  600 mg  twice  daily (bid)  in  AstraZeneca-sponsored, investigator-sponsored, and 
collaborative group studies. The recommended monotherapy tablet dose of olaparib is 300 mg 
bid.  Olaparib  is  generally  well  tolerated  at  monotherapy  doses  of  300 mg  bid  (tablet 
formulation) in subjects with solid tumors. Toxicities such as hematological, gastrointestinal, 
eg, nausea, vomiting and diarrhea, anorexia, dysgeusia, fatigues, etc., are generally Grade 1 or 
Grade 2. 
 
This study will use olaparib at the recommended monotherapy tablet dose of 300 mg bid. 
 
1.5.2    Rationale for Durvalumab fixed dosing 
 
A population PK model was developed for durvalumab using monotherapy data from a Phase 
1 study (study 1108; N=292; doses= 0.1 to 10 mg/kg Q2W or 15 mg/kg Q3W; solid tumors). 
Population PK analysis indicated only minor impact of body weight (WT) on PK of durvalumab 
(coefficient of ≤ 0.5). The impact of body WT-based (10 mg/kg Q2W) and fixed dosing (750 
mg Q2W) of durvalumab was evaluated by comparing predicted steady state PK concentrations 
(5th, median and 95th percentiles) using the population PK model. A fixed dose of 750 mg was 
selected to approximate 10 mg/kg (based on median body WT of ~75 kg). A total of 1000 
patients were simulated using body WT distribution of 40–120 kg. Simulation results 
demonstrate that body WT-based and fixed dosing regimens yield similar median steady state 
PK concentrations with slightly less overall between-subject variability with fixed dosing 
regimen. 
 
Similar findings have been reported by others.29,30,31,32,33 Wang and colleagues investigated 12 
monoclonal antibodies and found that fixed- and body size-based dosing perform similarly, with 
fixed dosing being better for 7 of 12 antibodies.30. In addition, they investigated 18 therapeutic 
proteins and peptides and showed that fixed dosing performed better for 12 of 18 in terms of 
reducing the between-subject variability in pharmacokinetic/pharmacodynamics parameters.31 
 
A fixed dosing approach is preferred by the prescribing community due to ease of use and 
reduced dosing errors. Given expectation of similar pharmacokinetic exposure and variability, 
we considered it feasible to switch to fixed dosing regimens. Based on average body WT of 75 
kg, a fixed dose of 1500 mg Q4W durvalumab (equivalent to 20 mg/kg Q4W) is included in the 
current study. Fixed dosing of durvalumab is recommended only for subjects with > 30kg body 

21(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
weight due to endotoxin exposure.  Patients with a body weight less than or equal to 30 kg 
should be dosed using a weight-based dosing schedule (Appendix D). 
 
 
 
1.5.3 Rationale for dose of olaparib in combination with durvalumab 
 
A recent phase 1 study presented results for durvalumab therapy in combination with 
olaparib for ovarian cancer and TNBC, at the American Society of Clinical Oncology (ASCO) 
2016. 10 ovarian cancer and 2 TNBC patients were included. Grade 3/4 adverse events 
included lymphopenia (2/12) and anemia (1/12).  1 PR (6 months) and 5 SD ≥ 4 months were 
seen in 9 evaluable patients, yielding a 67% disease control rate (DCR).33 
 
Dosage of olaparib tablets 300 mg bid along with durvalumab 1500 mg Q4W was tolerated 
and efficacious in these patients who did not possess germline BRCA mutations, and is the 
recommended phase 2 dose (RP2D) employed in this study. 33 

22(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
 
2    STUDY OBJECTIVES 
 
2.1    Primary objective 
 
To determine the efficacy as assessed by PFS (based on RECIST 1.1) of maintenance olaparib 
or olaparib in combination with durvalumab following clinical benefit (complete response [CR], 
partial response [PR] or stable disease [SD]) with platinum based chemotherapy in the 1st or 2nd 
line setting for treatment of metastatic triple negative breast cancer (mTNBC). 
 
2.2     Secondary objectives 
 
• To determine  the  efficacy  of  maintenance  olaparib  following  platinum  based 
chemotherapy as assessed by overall survival (OS). 
 
• To determine the efficacy of maintenance olaparib in combination with durvalumab 
following platinum based chemotherapy as assessed by overall survival (OS). 
 
• To determine the safety and tolerability of maintenance olaparib. 
 
• To determine the safety and tolerability of maintenance olaparib in combination with 
durvalumab. 
 
• To  determine the   efficacy  of   maintenance  olaparib  following  platinum-based 
chemotherapy as assessed by overall response rate (ORR) based on RECIST 1.1. 
 
• To determine the efficacy of maintenance olaparib in combination with durvalumab 
following platinum-based chemotherapy as assessed by overall response rate (ORR) 
based on RECIST 1.1. 
 
• To  determine the   efficacy  of   maintenance  olaparib  following  platinum-based 
chemotherapy as assessed by clinical benefit rate (CBR) based on RECIST 1.1. 
 
• To determine the efficacy of maintenance olaparib in combination with durvalumab 
following platinum-based chemotherapy as assessed by clinical benefit rate (CBR) based 
on RECIST 1.1. 
 
 
 
 
2.3    Exploratory objectives 
 
• To characterize the molecular epidemiology of biomarkers in TNBC through whole 
exome sequencing and immunohistochemistry studies. 
 
• To explore the immune microenvironment of TNBC including, but not limited to, tumor- 
infiltrating lymphocytes (TILs), macrophages and others. 

23(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
• To explore the tumor immunosuppressive microenvironment including but not limited 
to programmed death-ligand- 1 status on tumor and associated tissues. 
 
• To analyze epigenetic changes in TNBC including, but not limited to, DNA methylation 
and non-coding RNAs such as miRNAs. 
 
• To validate the role of minimally invasive blood-based markers such as circulating 
tumor cells or plasma DNA 
 
• To perform mutational analysis on normal germline DNA obtained from blood samples 
and buccal swabs. 
 
• Through systematic acquisition of tumor biopsies, additional tissue will be banked in 
the Duke Pathology central biorepository for future genetic research; it represents an 
invaluable resource toward achieving a deeper understanding of the mechanism of 
resistance or response to olaparib and or durvalumab. 
 
• To compare patients randomized to olaparib and olaparib in combination with the 
durvalumab arm on their efficacy outcome measures. 
 
• To  determine  the  efficacy  as  assessed  by  PFS,  ORR,  duration  of  response  of 
maintenance olaparib in combination with durvalumab based on iRECIST criteria 

24(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
Durvalumab 
Durvalumab 
R A N D O M I Z E D 
 
 
 
 
3    STUDY DESIGN 
 
3.1    Overall study structure and flow chart 
 
This is a randomized, international, multicenter, Phase II study designed to explore the efficacy 
of olaparib or olaparib in combination with durvalumab in platinum-treated mTNBC (See 
Figure 1). The primary objectives are to explore olaparib or olaparib in combination with 
durvalumab as maintenance therapy following clinical benefit with platinum-based therapy in 
subjects with mTNBC. 
 
Figure 1: Study Schema 
 
 
 
 
Mandatory blood and tissue 
banking (archival tissue or 
fresh tissue biopsy) 
1° Endpoint = PFS 
2° Endpoint = OS, toxicity, ORR 
Exploratory = biomarker analyses 
 
 
Eligibility: 
Advanced / Met TNBC 
 
 
Non PD on platinum 
chemo (1L/2L) 
Olaparib 300mg bid daily 
Till PD 
 
Olaparib 300mg bid daily 
 
 
Till PD 
 
 
 
 
Durvalumab 1500mg q4 weeks 
 
CT q8 weeks 
 
 
Approximately 60 subjects with mTNBC who are receiving platinum-based chemotherapy and 
who have had no more than 2 lines of chemotherapy in the metastatic or advanced setting, with 
one of those being a platinum, will be enrolled. Subjects will be eligible for this study following a 
minimum of three 3-weekly cycles or six 1-weekly doses of platinum-based (cisplatin or 
carboplatin) chemotherapy as single agent or combination therapy as prescribed by their treating 
physician.  Subjects can continue with further cycles of chemotherapy or be randomized any 
time after eligibility to allow for screening procedures to proceed without interruption of 
ongoing treatment. Subjects deriving clinical benefit (CR / PR / SD) with platinum-based 
therapy as determined by the treating physician will be eligible and randomized in a 1:1 ratio 
stratified by site and by the line of chemotherapy (in the metastatic setting). Randomization will 
be used to allocate subjects to either the olaparib or olaparib in combination with durvalumab 
arm, and comparisons between treatment regimens are planned as an exploratory objective. The 
purpose of randomization was to reduce bias due to subject selection into either treatment arm. 

25(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
Germline BRCA mutation testing is not mandated for entry onto the trial; however, previous 
BRCA test data will be collected to ascertain the number of known BRCA mutation carriers -- 
which will be limited to 10 in total. 
 
Tumor status will be evaluated as per RECIST v1.1 criteria. Tumor measurement for disease 
evaluation will be performed every 8 weeks on both arms, regardless of initial response to 
platinum chemotherapy. Estimation of PFS, duration of response and tumor response will be 
based on RECIST v1.1. 
 
Following randomization, subjects will discontinue platinum chemotherapy and receive either 
olaparib tablets or olaparib in combination with durvalumab. Study treatment should commence 
following resolution of chemotherapy toxicities to CTCAE grade 2 or less and no more than 4 
weeks after last dose of chemotherapy. Study treatment will continue until disease progression, 
intolerable toxicity, elective withdrawal from the study, or study completion or termination. 
Upon treatment discontinuation, subjects will be followed every 2 months for survival. 
 
Safety will be evaluated on an ongoing basis in this study through the monitoring of all serious 
and non-serious adverse events, graded according to National Cancer Institute Common 
Terminology Criteria for Adverse Events, Version 4.03 (NCI CTCAEv4.03). 
 
3.2    Rationale for study design, doses and control groups 
 
Subjects suitable for enrollment into this trial are adult subjects with histologically documented 
triple negative adenocarcinoma of the breast that is inoperable, locally advanced, or metastatic, 
and is not amenable to resection with curative intent, and who have received platinum-based 
chemotherapy in the 1st or 2nd line setting. 
 
Randomization will be used to allocate subjects to either the olaparib or olaparib in combination 
with durvalumab arm, and comparisons between treatment regimens are planned. The purpose 
of randomization is to reduce bias due to subject selection into either treatment arm. 
 
3.3    Rationale for prior treatment with platinum 
 
The standard of care chemotherapeutic agent for unselected and advanced TNBC include taxane 
chemotherapy. A growing body of preclinical and clinical data suggests that platinum 
chemotherapy has a role to play in the treatment of both early and advanced TNBC, based on 
the hypothesis of greater susceptibility of TNBC to DNA-damaging chemotherapy agents. 
Clinical activity of the platinum combination (gemcitabine / cisplatin) has previously been 
evaluated with a response rate of around 30%34. The TNT trial evaluated 6 cycles of platinum 
therapy with monotherapy carboplatin dosed at area under the curve (AUC) 6 every 3 weekly 
in comparison to 6 cycles of taxane therapy with docetaxel dosed at 100mg/m2 every 3 weeks 
with the option of crossover upon treatment progression or toxicity in patients who had not 
previously received treatment for advanced TNBC. In the overall population, there was no 
difference between the ORR to carboplatin and to docetaxel 31.4% versus 34.0% (absolute 
difference -2.6%, 95% CI -12.1 to 6.9; p=0.66). There was no difference in median PFS 3.1 
months (95% CI 2.4-4.2) versus 4.4 months (95% CI 4.1-5.1) or OS, 12.8 months (95% CI 10.6- 
15.3) versus 12.0 months (95% CI, 10.2-13.0) in both treatment groups. Patients with a 

26(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
deleterious mutation in BRCA1/2 genes had a significantly better ORR to carboplatin than 
docetaxel (ORR 68% versus 33.3%; p=0.03). PFS was also longer 6.8 months versus 4.4 
months; p=0.002. No difference was observed based on response to crossover treatment with 
the alternative drug. Thus platinum chemotherapy represents a widely used and appropriate 
therapy for subjects in the first / second line setting35. 
 
3.4    Inclusion Criteria 
 
Subjects must meet all of the below criteria to be eligible for randomization and study treatment. 
 
 
1.   Age ≥ 21 years of age 
 
2.   ECOG performance status 0-2 
 
3.   Inoperable locally advanced or metastatic breast cancer not amenable to resection with 
curative intent and histologically confirmed to be estrogen receptor (ER) negative, 
progesterone receptor (PR) negative, and HER2 negative: 
 
• 
ER negative status is defined as < 1% tumor cells positive for ER by 
immunohistochemistry (IHC), irrespective of staining intensity 
• 
PR negative status is defined as < 1% tumor cells positive for PR by IHC, 
irrespective of staining intensity 
• 
NOTE: Enrollment is permitted for ER/PR low-expression subjects (defined as ≤ 
 
10 %) who are expected to benefit from this trial at the investigator’s discretion. 
 
• 
HER2 negative status is determined by: 
 
• 
IHC 1+, as defined by incomplete membrane staining that 
is faint/barely perceptible and within > 10% of invasive 
tumor cells, or 
• 
IHC 0, as defined by no staining observed or membrane 
staining that is incomplete and is faint/barely perceptible 
and within ≤ 10% of the invasive tumor cells, or 
• 
FISH negative based on: 
 
• 
Single-probe average HER2 copy number 
 
< 4.0 signals / cell, or 
 
• 
Dual-probe HER2/CEP17 ratio < 2.0 with 
an average HER2 copy number < 4.0 
signals / cell 

27(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
4.  Minimum six 1-weekly doses or three 3-weekly doses of platinum chemotherapy 
(monotherapy or combination therapy at investigator’s discretion) with stable disease 
(SD), partial response (PR) or complete response (CR) to the platinum therapy as 
assessed by investigator. 
5.   Has received no more than 2 prior chemotherapy lines for metastatic breast cancer 
including current platinum-based chemotherapy. 
6.   Able to provide a representative formalin-fixed, paraffin embedded tumor specimen 
archival or fresh tissue for correlative studies and biomarker analysis. 
7.   Hemoglobin ≥ 9.0 g/dL and no blood transfusions in the 28 days prior to study entry. 
 
Absolute neutrophil count ≥1,500/mm3. Platelet count ≥100 x 10^9/L. 
 
 
8.   Total bilirubin <1.5 x the upper limit of normal (ULN) with the following exception: 
subjects with known Gilbert's disease who have serum bilirubin <3 x ULN may be 
enrolled. 
 
9.   Aspartate transaminase (AST) and alanine transaminase (ALT) <2.5 x ULN with the 
following exceptions: subjects with documented liver or bone metastases may have AST 
and ALT <5 x ULN. 
 
10. Alkaline phosphatase (ALP) <2 x ULN (<5 x ULN in subjects with known liver 
involvement and <7 ULN in subjects with known bone involvement). 
 
11. Serum creatinine <1.5 x ULN or creatinine clearance >51 mL/min by the Cockcroft- 
Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for 
determination of creatinine clearance. 
 
12. For subjects of childbearing potential, agreement (by both subject and partner) to use 
two effective forms of contraception, including surgical sterilization, reliable barrier 
method, birth control pills, contraceptive hormone implants, or true abstinence and to 
continue its use for the duration of the study and for 3 months after last dose of study 
treatment. 
 
13. Subjects of childbearing potential should have a negative urine or serum pregnancy test 
during their screening visit. If the urine test is positive or cannot be confirmed as 
negative, a serum pregnancy test will be required. 

28(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
14. Subjects willing and able to comply with the protocol for the duration of the study 
including undergoing treatment and scheduled visits and examination. 
 
15. For inclusion in genetic research, subjects must provide informed consent for genetic 
research collection of specimens to be stored at repository for future research. 
 
3.5 
Exclusion Criteria 
 
Subjects should not enter the study if any of the following exclusion criteria are fulfilled. 
 
1. 
Currently participating and receiving study therapy or has participated in a study of an 
investigational agent and received study therapy or used an investigation device within 
4 weeks of first dose of treatment. Subjects who have entered the follow-up phase of an 
investigational study may participate as long as it has been 4 weeks since last dose of 
the previous investigational agent of device. 
 
2. 
Concurrent  enrollment  in  another  clinical  study,  unless  it  is  an  observational 
(non-interventional) clinical study or the follow-up period of an interventional study. 
 
3. 
Active autoimmune disease that has required systemic treatment in past 2 years (ie, with 
use of disease modifying agents, corticosteroids or immunosuppressive drugs). 
Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement 
therapy for adrenal or pituitary insufficiency, or similar treatment) is not considered a 
form of systemic treatment. 
 
4. 
Is taking chronic systemic steroids in doses > 10mg of prednisolone or equivalent within 
7 days prior to the first dose of trial treatment. 
 
5. 
Previous treatment with PARP inhibitors including olaparib. 
 
6. 
Patients that have required discontinuation of treatment due to treatment-related toxicities 
from prior therapy with PD-1, PDL-1 or CTLA-4 inhibitors or previous history of 
immune-related grade 3 or 4 adverse event.  
 
7. 
Known active central nervous system metastasis and / or carcinomatous meningitis. 
Subjects with previously treated brain metastases may participate, provided they have: 
 
a. 
Stable brain metastases [without evidence of progression by imaging (confirmed by 
computerized tomography {CT} scan if CT used at prior imaging) for at least four 
weeks prior to the first dose of trial treatment**, 
 
b. 
No evidence of new or enlarging brain metastases; any neurologic symptoms should 
have returned to baseline, 
 
c. 
Not used steroids for brain metastases in the 7 days prior to trial initiation. Taking 
chronic systemic steroids in doses ≤ 10mg of prednisolone is allowed. 

29(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
**This exception does not include carcinomatous meningitis, as  subjects with 
carcinomatous meningitis are excluded regardless of clinical stability. 
 
8. 
History and/or confirmed pneumonitis, or extensive bilateral lung disease on high 
resolution/spiral CT scan. 
 
9. 
Patients with  suspected  or  confirmed  myelodysplastic  syndrome/acute  myeloid 
leukemia. 
 
10. 
History of another primary malignancy except for: 
 
a.   Malignancy treated with curative intent and with no known active disease ≥5 years 
before the first dose of study drug and of low potential risk for recurrence. 
 
b.   Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of 
disease. 
 
c.   Adequately treated carcinoma in situ without evidence of disease eg, cervical cancer in 
situ. 
 
11. 
Major surgery within 2 weeks of starting the study, and subjects must have recovered 
from any effects of any major surgery. 
 
12. 
Receipt of radiation therapy within 4 weeks prior to starting study drug(s). Limited field 
of radiation for palliation within 2 weeks of the first dose of study treatment is allowed 
provided: 
 
a.   The lung is not in the radiation field 
 
b.   Irradiated lesion(s) cannot be used as target lesions 
 
13. 
Uncontrolled  intercurrent  illness  including,  but  not  limited  to,  ongoing  or  active 
infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable 
angina pectoris, cardiac arrhythmia, active peptic ulcer disease, active bleeding diatheses 
including any subjects known to have evidence of acute or chronic hepatitis B, hepatitis 
C or human immunodeficiency virus (HIV), or psychiatric illness / social situations that 
would limit compliance with study requirements or compromise the ability of the subject 
to give written informed consent. 
 
14. 
Subjects  unable  to  swallow  orally  administered  medication,  and  subjects  with 
gastrointestinal disorders likely to interfere with absorption of the study medication. 
 
15. 
Subjects requiring treatment with potent inhibitors or inducers of CYP3A4. 
 
16. 
Pregnant or breast-feeding women. If breastfeeding can be stopped prior to study 
enrollment until 1 month after the last study dose, then the patient could be allowed to 
enter the study. 

30(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
17. 
Immunodeficient subjects, eg, subjects who are known to be serologically positive for 
human immunodeficiency virus (HIV). 
 
18. 
Received a live vaccine within 30 days of planned start of study therapy. 
 
19. 
Subjects with a known hypersensitivity to olaparib or durvalumab, or any of the 
excipients of the product. 
 
20. 
Active or prior documented inflammatory bowel disease (eg, Crohn’s disease, ulcerative 
colitis) 
 
21. 
History of allogeneic organ transplant 
 
22. 
Active bleeding diatheses 
 
23. 
Patients with known active hepatic disease (ie, Hepatitis B or C) 
 
24. 
Known history of previous clinical diagnosis of tuberculosis. 
 
For procedures for withdrawal of incorrectly enrolled subjects, see Section 5.3. 
 
3.6 
Restrictions during the study 
 
The following restrictions apply while the patient is receiving study treatment and for the 
specified times before and after: 
 
 
3.6.1 Pregnancy/Breastfeeding 
 
1. 
Female  subjects  of  childbearing  potential  who  are  sexually  active  with  a 
non-sterilized male partner must use two highly effective methods of contraception 
(Table 1) from the time of screening and must agree to continue using such 
precautions for at least 1 month after the last dose of olaparib or at least 3 months 
after the last dose of durvalumab.  Male partners of a female subject must use male 
condom plus spermicide throughout this period. Cessation of birth control after this 
point should be discussed with a responsible physician. 
 
2. 
Total sexual abstinence or engaging in sexual activity for the total duration of the trial 
and the drug washout period (1 month after the last dose) is an acceptable practice; 
however, occasional abstinence, the rhythm method, and the withdrawal method are 
not acceptable methods of contraception. Female patients should refrain from 
breastfeeding throughout this period. 
 
3. 
Non-sterilized male subjects who  are sexually active with  a  female partner of 
childbearing potential must use male condom plus spermicide from screening through 
at least 1 month after the last dose of olaparib or at least 3 months after the last dose 
of durvalumab. Not engaging in sexual activity for the total duration of the trial and 
the drug washout period (1 month after the last dose of olaparib or 3 months after the 

31(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
last dose of durvalumab) is an acceptable practice; however, occasional abstinence, 
the rhythm method, and the withdrawal method are not acceptable methods of 
contraception. Male patients should refrain from sperm donation throughout this 
period. Female partners of a male subject must use a highly effective method of 
contraception throughout this period. 
 
4. 
Females of childbearing potential are defined as those who are not surgically sterile 
(i.e., bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or 
postmenopausal (defined as 12 months with no menses without an alternative medical 
cause). 
 
5. 
Highly effective methods  of  contraception are  described in  Table 1.  A  highly 
effective method of contraception is defined as one that results in a low failure rate 
(ie, less than 1% per year) when used consistently and correctly. Note that some 
contraception methods are not considered highly effective (eg, male or female 
condom with or without spermicide; female cap, diaphragm, or sponge with or 
without spermicide; non-copper containing intrauterine device; progestogen-only oral 
hormonal contraceptive pills where inhibition of ovulation is not the primary mode 
of action [excluding Cerazette/desogestrel, which is considered highly effective]; and 
triphasic combined oral contraceptive pills). 
 
Table 1: Highly Effectivea Methods of Contraception 
 
Barrier/Intrauterine Methods 
Hormonal Methods 
• 
Copper T intrauterine device 
• 
Levonorgestrel-releasing intrauterine 
system (eg, Mirena®)b 
• 
“Implants”: Etonogestrel-releasing 
implants: eg, Implanon® or Norplant® 
• 
“Intravaginal Devices”: 
Ethinylestradiol/etonogestrel-releasing 
intravaginal devices: eg,NuvaRing® 
• 
“Injection”: Medroxyprogesterone 
injection: eg, Depo-Provera® 
• 
“Combined Pill”: Normal and low dose 
combined oral contraceptive pill 
• 
“Patch”: 
Norelgestromin/ethinylestradiol- 
releasing transdermal system: eg, Ortho 
Evra® 
• 
“Minipill”: Progesterone based oral 
contraceptive pill using desogestrel: 
eg, Cerazette® 
a 
Highly effective (ie, failure rate of <1% per year) 
b 
This is also considered a hormonal method 
c 
Cerazette® is currently the only highly effective progesterone-based pill 
 
 
 
 
Contraception 

32(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
Subjects with child-bearing potential and their partners, who are sexually active, must agree to 
the use of two highly effective forms of contraception throughout their participation in the study 
and for 3 months after last dose of study drug(s). 
 
• Condom with spermicide 
 
and one of the following: 
 
• Oral contraceptive or hormonal therapy (eg, hormone implants) 
 
• Placement of an intra-uterine device 
 
Acceptable non-hormonal birth control methods include: 
 
Total sexual abstinence. Abstinence must be prior to study enrollment, for the total duration of 
the study, and one month after last dose. Vasectomized sexual partner plus male 
condom, with participant assurance that partner received post-vasectomy 
confirmation of azoospermia 
 
•           Tubal occlusion plus male condom with spermicide 
 
• 
Intrauterine Device (IUD) plus male condom+spermicide, provided coils are copper- 
banded 
 
Acceptable hormonal methods: 
 
** The efficacy of hormonal contraceptives may be reduced if co-administered with olaparib.** 
 
•           Etonogestrel implants (eg, Implanon, Norplan)+male condom with spermicide 
 
•           Normal and low dose combined oral pills+male condom with spermicide 
 
•           Norelgestromin/ethinyl estradiol transdermal system+male condom with spermicide 
 
• 
Intravaginal  device+male  condom  with  spermicide  (eg,  ethinyl  estradiol  and 
etonogestrel) 
 
• 
Cerazette (desogestrel)+male condom with spermicide. Cerazette is currently the 
only highly efficacious progesterone-based pill. 
 
3.6.2    Surgery 
 
Olaparib treatment should be stopped at least 3 days prior to planned surgery. After surgery 
olaparib can be restarted when the wound has healed. No stoppage of olaparib is required for 
any needle biopsy procedure. 

33(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
3.6.3    Radiation 
 
Palliative radiotherapy may be used for the treatment of pain at the site of bony metastases that 
were present at baseline, provided the Investigator is not of the opinion that these are indicative 
of clinical disease progression during the study period. Full details of all these treatments are 
recorded in the subject’s notes and appropriate section of the eCRF. Study treatment should be 
discontinued for a minimum of 3 days before the subject undergoes palliative radiation 
treatment. Study treatment should be restarted within 4 weeks as long as any bone marrow 
toxicity has recovered. 
 
3.6.4    Administration of other anti-cancer agents 
 
Subjects must not receive any other concurrent anti-cancer therapy, including investigational 
agents, while on study treatment. Subjects may continue the use of bisphosphonates for bone 
disease and corticosteroids for the symptomatic control of brain metastases, provided the dose 
is stable in the last 7 days and does not exceed 10mg of prednisolone or equivalent. 
 
.Full details of all of these treatments are recorded in the subject’s notes and appropriate section 
of the eCRF. 
 
3.6.5    Blood donation 
 
Subjects should not donate blood while participating in this study or for at least 90 days 
following the last infusion of durvalumab, or until at least 3 days after the last administration of 
olaparib. 
 
3.6.6    Other concomitant treatment and medications 
 
1. 
No  other  chemotherapy  specified  outside  of  this  protocol,  hormonal  therapy 
(hormone replacement therapy [HRT] is acceptable), or other novel agent is to be 
permitted during the course of the study for any subject (the subject can receive a 
stable low dose of corticosteroids during the study, as per exclusion criteria above). 
 
2. 
Live virus and bacterial vaccines should not be administered while the subject is 
receiving study medication and during the 30-day follow-up period. An increased risk 
of infection resulting from administration of live virus and bacterial vaccines has been 
observed with conventional chemotherapy drugs; the effects with olaparib are 
unknown. 
 
3. 
Subjects should avoid concomitant use of drugs, herbal supplements, and/or ingestion 
of foods known to modulate CYP3A4 enzyme activity from the time they enter the 
screening period until 30 days after the last dose of study medication. In vitro data 
have shown that the principal enzyme responsible for the formation of the 3 main 
metabolites of olaparib is CYP3A4, and consequently, this restriction is required to 
ensure subject safety. 
 
4. 
Concomitant  use  of  strong  CYP3A  inhibitors  (eg,  itraconazole,  telithromycin, 
clarithromycin, ketoconazole, voriconazole, nefazodone, posaconazole, ritonavir, 

34(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
lopinavir/ritonavir, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) and 
moderate CYP3A inhibitors (e.g., amprenavir, aprepitant, atazanavir, ciprofloxacin, 
crizotinib, darunavir/ritonavir, diltiazem, erythromycin, fluconazole. Fosamprenavir, 
imatinib, verapamil) is not allowed. 
 
5. 
Concomitant   use   of   strong   CYP3A   inducers   (eg,   phenytoin,   rifampicin, 
carbamazepine, St. John’s Wort) and moderate CYP3A inducers (eg, bosentan, 
efavirenz, etravirine, modafinil, nafcillin) is not allowed. 
 
6. 
Immunosuppressive medications should not be given concomitantly or given as a 
premedication prior to infusion. This includes but is not limited to systemic 
corticosteroids at doses not exceeding 10 mg/day of prednisone or equivalent, 
methotrexate, azathioprine, and tumor necrosis factor-alpha (TNF-α) blockers. 
 
The following are allowed exceptions: 
• Use of immunosuppressive medications for the management of durvalumab-related 
AEs, 
• Short-term steroid premedication for patients receiving durvalumab if required for 
documented hypersensitivity reactions. 
• Use in patients with contrast allergies as a premedication/prep prior to scans. 
• In addition, use of inhaled, topical, and intranasal corticosteroids is permitted. 
 
 
7. 
Subjects who  are taking warfarin may participate in this study;  however, it is 
recommended that prothrombin time (INR and APTT) be monitored carefully at least 
once per week for the first month, then monthly if the INR is stable. Subcutaneous 
heparin is permitted. The reason(s) for the use, doses, and dates of treatment should 
be recorded in the subject’s medical records and appropriate section of the eCRF. 
 
8. 
All medications (prescriptions or over-the-counter medications) continued at the start 
of the trial or started during the study or until 30 days from the end of the last protocol 
treatment and that are different from the study medication must be documented. 
 
3.7    Data Management 
 
Data Management will be performed by Duke Clinical Research Institute (DCRI). DCRI is 
responsible for the development of a 21 CFR Part 11-compliant electronic data management 
system. This system will include eCRF screens, automated data validation checks and a 
randomization module. The data validation checks include checks for out-of-range and logically 
inconsistent data. 
 
The DCRI will be responsible for medical coding. Adverse events will be coded using DCRI’s 
current version of the medical dictionary for regulatory activities (MedDRA) updated semi- 
annually. The concomitant medications will be coded using DCRI’s current version of the 
World Health Organization Drug Dictionary Enhanced (WHO DDE) updated semi-annually. 

35(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
Protocol specific data management activities will be defined in the Data Management Plan. 
Quality control procedures will be applied to each stage of data handling to ensure that all data 
are reliable and have been processed correctly. 
 
When all data have been coded, validated and locked, a clean file will be declared. 
 
3.8    Evaluation and calculation of variables 
 
The primary efficacy outcome measure is as follows: 
 
• PFS (progression free survival) defined as the time from randomization to the first 
occurrence of disease progression (as determined using RECIST 1.1 criteria and assessed 
by the Investigator) or death from any cause on study. Death on study is defined as death 
from any cause within 30 days of the last dose of study treatment regimen. Tumor 
progression will be assessed locally at each site by the investigators according to RECIST 
1.1. No independent review of tumor progression is planned. PFS with disease 
progression determined by iRECIST for patients on the combination arm will also be 
examined in exploratory data analysis. 
 
The secondary efficacy outcome measures in all subjects are as follows: 
 
• OS (overall survival) defined as the time from entry onto trial until death from any cause. 
 
• ORR (overall response rate) defined as the subjects achieving Complete Response or 
Partial Response as defined by RECIST 1.1. 
 
• CBR (clinical benefit rate) defined as subjects achieving Complete Response, Partial 
Response or Stable disease ≥ 24 weeks 
 
 
 
 
3.9    Calculation or derivation of efficacy variable(s) 
 
The following definitions and criteria (from RECIST 1.1) should be used for the baseline 
evaluations of existing disease, and for the ongoing evaluation of tumor responses. All 
measurements should be taken and recorded in metric notation, using a ruler or callipers. For 
the case of skin lesions, documentation (jpg file, preferred) by color photography, and a 
measurement with a ruler to estimate the size of the lesion, is recommended. 
 
• Measurable disease - the presence of at least one measurable lesion. 
 
• Measurable lesions - lesions that can be accurately measured in at least one dimension 
with longest diameter (LD) 20 mm using conventional techniques or 10 mm with spiral 
CT scan. Lymph nodes must be 15mm or greater (by spiral CT) in the shortest diameter 
to be considered measureable. 

36(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
• Non-measurable lesions - all other lesions, including small lesions (LD <20 mm with 
conventional techniques or <10 mm, Lymph nodes <15mm SD with spiral CT scan), ie, 
bone lesions, ascites, pleural/pericardial effusion, cystic lesions, and also abdominal 
masses that are not confirmed and followed by imaging techniques. 
 
Conventional CT should be performed with cuts of 10 mm or less in slice thickness 
contiguously. Spiral CT should be performed using a 5-mm contiguous reconstruction algorithm. 
 
All imaging methods should be performed according to institutional standards with each subject 
having consistency of methods beginning from baseline through the course of the study. 
 
3.9.1    Evaluation of Best Overall Response 
 
The best overall response is the best response recorded from the start of the treatment until 
disease progression and is determined as per Tables 10 and 11. 
 
To be considered a response, CR or PR must persist for a minimum of 4 weeks. If, at the time 
of tumor response evaluation, either a PR or CR is observed, the same radiographic study should 
be repeated four weeks later for confirmation of response. After this confirmatory study, 
subjects should return to the schedule of evaluations as previously described. 
 
 
 
 
4    STUDY PROCEDURES AND ASSESSMENTS 
 
The schedule of assessments is provided in Appendix A. Descriptions of the scheduled 
evaluations are outlined below and complete information on study drugs and dosing is provided. 
 
Before study entry, throughout the study, and at the follow-up evaluation, various clinical and 
diagnostic laboratory evaluations are outlined. The purpose of obtaining these detailed 
measurements is to ensure adequate safety and tolerability assessments. Clinical evaluations and 
laboratory studies may be repeated more frequently if clinically indicated. This study will use 
local site labs for laboratory testing and for safety laboratory evaluations; biomarker specimens 
collected will be stored at study sites until end of study then shipped to the Duke Pathology 
central biorepository for future research. 
 
 
 
4.1    Subject enrollment and randomization 
 
4.1.1     Informed consent 
 
Investigators must ensure that subjects are clearly and fully informed about the purpose, 
potential risks, and other critical issues regarding this clinical study for which they are 
volunteering to participate. 
 
Before any study procedures are performed, potential subjects will have the outline of the study 
described to them, and they will be given a written informed consent document to read. If they 
consent to participate in the study, they will indicate that consent by signing and dating the 
informed consent document in the presence of study personnel. Any subject who signs the 

37(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
consent form will be considered a “screened” subject. 
 
4.1.2    Screening Procedures 
 
After written informed consent is obtained according to ICH GCP and local regulations, the 
subject’s eligibility for the study and baseline disease status will be evaluated. This will occur 
in a screening visit during which the following will be evaluated and documented within 14 days 
prior to first dose of study drug(s). 
 
Investigations, such as CT or MRI scans that have been performed as part of routine clinical 
practice, can be used as part of the screening process if performed within 28 days of first dose 
of study treatment; however, no non-standard of care investigations or tests that are study 
specific and required for screening may be performed prior to signature of the informed consent 
form. 
 
The following baseline information should be obtained within 28 days prior to randomization: 
 
• 
Demographic data and medical history, including previous and current diseases and 
medications, and confirmation of all prior treatments for metastatic breast cancer, 
including platinum based treatment requirements of investigator choice. 
 
• 
Check availability of archival tumor tissue sample or new tumor biopsy if archival tissue 
unavailable 
 
• 
Baseline adverse events to document pre-existing toxicity from prior treatment (assessed 
using CTCAE v4.03) 
 
• 
Tumor response to platinum based chemotherapy, evaluation by CT or MRI (as defined 
by investigator assessment) 
 
• 
Physical examination including the assessment of height, weight, pulse rate and blood 
pressure and BMI. 
 
•       Eastern Cooperative Oncology Group (ECOG) performance status 
 
•       Blood testsb 
 
 
Full blood count (CBC with differential) 
 
 
U&E: serum creatinine (SCr), urea, K+, Na+, glomerular filtration rate 
assessment 
 
 
Liver function test: Bilirubin, ALP, AST/ALT, albumin 
 
•       Radiological investigations 
 
 
CT or MRI scan to assess disease (thorax, abdomen and pelvis) 
 
•       Other tests 
 
 
Pregnancy tests 
 
See Appendix G for additional requirements for Korean sites only. 
 
Where laboratory investigations have not been performed within the 7-day period prior to 
starting treatment, they must be repeated on day 1 of cycle 1. 
 
4.1.3   Baseline documentation of “target” and “non-target” lesions 

38(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
All measurable lesions (nodal and non-nodal) up to a maximum of five lesions in total (and a 
maximum of 2 lesions per organ), representative of all involved organs, should be identified as 
target lesions and recorded and measured at baseline. Target lesions must be 10 mm in the 
longest diameter to qualify, or 15 mm in the short diameter for lymph nodes. Target lesions 
should be selected on the basis of their size (lesions with the longest diameter) and their 
suitability for accurate repeated measurements (either by imaging techniques or clinical 
assessments). 
 
A sum of the longest diameter (LD) for all target lesions will be calculated and reported as the 
baseline sum LD. The baseline sum LD will be used as the reference by which to characterize 
the objective tumor response. 
 
All other lesions (or sites of disease) should be identified as non-target lesions and should also 
be recorded at baseline. Measurements of these lesions are not required, but the presence or 
absence of each should be noted throughout follow-up. 
 
4.1.4    Enrollment procedures 
 
Subjects deriving clinical benefit (CR / PR / SD) with platinum-based therapy will be 
randomized to each of the treatment arms (olaparib or olaparib in combination with durvalumab) 
through the use of a stratified permuted block randomization in a 1:1 ratio to ensure within-stratum 
balance of characteristics between treatment arms. The stratification will be based on line of 
chemotherapy and by site.  Randomization will be used to allocate subjects to either the olaparib 
or olaparib in combination with the durvalumab arm, and comparisons between treatment 
regimens are planned. The purpose of randomization is to reduce bias due to subject selection into 
either treatment arm. 
 
There are five institutions participating as study sites in three countries including USA, 
Singapore, and South Korea.  Each site will complete an eligibility checklist and enrollment 
must be submitted and approved prior to the randomization of any subject. The details of this 
procedure is provided in the site initiation materials. 
 
4.1.5   Post-platinum chemotherapy tumor evaluation 
 
Initial tumor assessment to assess for response to platinum chemotherapy will be performed as 
per standard of care following at least three 3-weekly (q21 day) or six 1-weekly doses of 
platinum chemotherapy. Attempts should be made to minimize time off treatment to less than 
3 weeks. Any measurable disease must be documented at screening and re-assessed at tumor 
evaluation. Measurable disease is not required to go on study. Response assessments will be 
performed by the Investigator on the basis of physical examinations and imaging scans. 
Eligibility requires stable disease (SD), partial response (PR) or complete response (CR) per 
investigator assessment to the platinum therapy. 
The same imaging method used at screening/baseline must be maintained throughout the study. 
Computerized  tomography  (CT)  scans  are  the  preferred  imaging  modality  for  tumor 
assessments. Tumor assessments should include a diagnostic quality contrast-enhanced CT scan 
of the chest, abdomen, and pelvis at baseline. Computerized tomography (CT) scans of the neck 
should be included if there is clinically indication. Subsequent tumor assessments should include 
CT scans of the chest, abdomen, pelvis, and other known sites of disease. In addition to the 

39(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
scheduled protocol scans, CT scans may be performed at the Investigator’s discretion at any time 
if progressive disease is suspected. 
 
In subjects for whom a CT scan is contraindicated because of an allergy to IV radiographic 
contrast, both CT scan of the chest without contrast and a magnetic resonance imaging (MRI) 
scan with contrast of the abdomen and pelvis and neck if clinically indicated are recommended; 
MRI scans may be performed in lieu of CT scans. Subsequent tumor assessments should include 
MRI scans of the chest, abdomen, pelvis, and other known sites of disease. The CT or MRI 
scans may be repeated at the Investigator’s discretion at any time if progressive disease is 
suspected. 
 
At the Investigator’s discretion and if clinically indicated, other methods of assessment of 
measurable disease per RECIST 1.1 may be used (eg, brain scans using CT or MRI) in addition 
to those listed above. Additional procedures for tumor assessment should be performed as 
clinically indicated. 
 
4.1.6      Procedures for randomization 
 
Subjects with CR, PR, or SD by investigator assessment following minimum requirements in 
inclusion criteria of platinum-based chemotherapy are eligible to consent and complete 
screening activities. Subjects who meet all eligibility requirements will be randomly allocated 
to each of the treatment arms (olaparib or olaparib in combination with durvalumab). 
 
Subjects will be allocated to each of the treatment arms (olaparib or olaparib in combination 
with durvalumab) through the use of a stratified permuted block randomization in a 1:1 ratio, to 
ensure within-stratum balance of characteristics between treatment arms. Randomization will 
be stratified by line of chemotherapy (1st vs 2nd) and by site. 
 
4.1.7     Procedures for handling ineligible or screen-fail subjects 
 
Subjects who signed the study informed consent form but are considered ineligible after 
screening will be considered as screening failures, and data will be handled as follows:  The 
demographic information, informed consent, and inclusion/exclusion criteria will be collected 
for screen failure subjects. No other data will be collected for subjects who are screen failures 
unless the subject experienced a serious adverse event during the screening phase that is possibly 
related to a study procedure. 
 
4.2     Treatments 
 
Subjects will continue on study drug(s) until objective disease progression, as long as in the 
Investigator’s opinion they are benefiting from treatment and they do not meet any other 
discontinuation criteria. 
 
4.2.1    Identity of investigational product(s) 
 
The AstraZeneca Pharmaceutical Development R&D Supply Chain will supply olaparib and the 
durvalumab to the Investigator/sponsor’s dispensing vendor. This vendor will distribute drug 
supply to the participating sites. 

40(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
Table 2: Identity of Investigational Product 
 
Investigational product 
Dosage form and strength 
Olaparib 
150 mg oral tablet and 100mg oral tablet 
(100mg for dose reductions only) 
Durvalumab 
1500 mg intravenous 
a 
Descriptive information for olaparib can be found in the Investigator’s Brochure 
 
4.2.2     Olaparib 
 
Olaparib (AZD 2281) (as film-coated tablet formulation) is intended for oral administration. The 
tablet monotherapy dose and the dose that will be used in this study is 300 mg bid taken 
continuously in 28 day cycles. 
 
4.2.3    Olaparib: doses and treatment regimens 
 
For all centers, olaparib tablets will be packed in high-density polyethylene (HDPE) bottles with 
child-resistant closures. Each dosing container will contain 32 tablets and desiccant. Multiple 
bottles of study treatment may be required for dispensing in order to make up the desired dose. 
 
Olaparib will be dispensed to subjects on Day 1 and approximately every 28 days thereafter 
until the subject completes the study, the subject withdraws from the study or closure of the 
study. 
The olaparib tablets should be swallowed whole and not chewed, crushed, dissolved, or divided. 
The effect of food on olaparib tablet has been investigated. Co-administration with food slowed 
the rate of absorption (tmax delayed by 2.5 hours and Cmax reduced by 20%), however food 
did not significantly affect AUC, therefore olaparib tablet formulation can be given without 
regard to food. 
 
If vomiting occurs shortly after the olaparib tablets are swallowed, the dose should only be 
replaced if all of the intact tablets can be seen and counted. Should any subject enrolled on the 
study miss a scheduled dose for whatever reason (eg, as a result of forgetting to take the tablets 
or vomiting), the subject will be allowed to take the scheduled dose up to a maximum of 2 hours 
after that scheduled dose time. If longer than 2 hours after the scheduled dose time, the missed 
dose is not to be taken and the subject should take their allotted dose at the next scheduled time. 
 
Subjects will continue with olaparib until objective disease progression (determined by RECIST) 
as long as in the Investigator’s opinion they are benefiting from treatment and they do not meet 
any other discontinuation criteria. 
 
4.2.4    Management of toxicity of olaparib 
 
Any toxicity observed during the course of the study could be managed by interruption and/or 
dose reduction of the dose if deemed appropriate by the Investigator. Repeat dose interruptions 
are allowed as required for a maximum of 14 days on each occasion. If the interruption is any 

41(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
longer than this, the sponsor or their designee must be informed. Olaparib must be interrupted 
until the subject recovers completely or the toxicity reverts to the National Cancer Institute 
(NCI) Common Terminology Criteria for Adverse Events version 4.03, grade 1 or less. 
 
Where toxicity reoccurs following re-challenge with olaparib, and where further dose 
interruptions are considered inadequate for management of toxicity, then the subject should be 
considered for dose reduction or must permanently discontinue treatment with olaparib. 
 
Treatment must be interrupted if any NCI-CTCAE grade 3 or 4 adverse event occurs that the 
Investigator considers to be related to administration of olaparib. 
 
All dose reductions and interruptions (including any missed doses), and the reasons for the 
reductions/interruptions are to be recorded in the electronic case record form (eCRF). 
 
Management of anemia 
 
Adverse  events  of  anemia CTCAE  grade  1  or  2  (Hemoglobin  [Hb]  >8 g/dl)  should  be 
investigated and managed as deemed appropriate by the Investigator with or without interruption 
of study drug or change in dose, taking into account previous history of anemia. Common  
treatable  causes  of  anemia (eg,  iron,  vitamin  B12  or  folate  deficiencies,  and 
hypothyroidism) should be excluded. In some cases, management of anemia may require blood 
transfusions. However, if a subject develops anemia CTCAE grade 3 (Hb <8 g/dl) or worse, 
study treatment should be interrupted for up to maximum of 4 weeks to allow for bone marrow 
recovery, and the subject should be managed appropriately. Study treatment can be restarted at 
the same dose if Hb has recovered to >10 g/dl or baseline. Any subsequently required anemia 
related interruptions, considered likely to be dose related, or coexistent with newly developed 
neutropenia, and or thrombocytopenia, will require Olaparib study treatment dose reductions to 
250 mg bid as a first step and to 200 mg bid as a second step. 
 
If a subject has been treated for anemia with multiple blood transfusions without study treatment 
interruptions and becomes blood-transfusion dependent—as judged by the Investigator— study 
treatment should be permanently discontinued. 
 
Management of neutropenia and leukopenia 
 
An adverse event of neutropenia and leukopenia should be managed as deemed appropriate by 
the Investigator with close follow-up and interruption of study drug if CTC grade 3 or worse 
neutropenia occurs. Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) 
is not recommended; however, if a subject develops febrile neutropenia, Olaparib study 
treatment should be stopped and appropriate management including G-CSF should be given 
according to local hospital guidelines. Please note that G-CSF should not be used within at least 
24 h of the last dose of Olaparib study treatment. 
 
Olaparib treatment can be restarted at the same dose if an adverse event of neutropenia or 
leucopenia  have  been  recovered  up  to  CTC  AE  grade  >1  (absolute  neutrophil  count 

42(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
>1.5 x 109/L). Growth factor support should be stopped at least 24h before restarting study drug 
(7 days for pegylated G-CSF). 
 
Any subsequent interruptions will require study treatment dose reductions to 250 mg bid as a 
first step and to 200 mg bid as a second step for a 300 mg monotherapy starting dose. 
 
Management of thrombocytopenia 
 
An adverse event of thrombocytopenia should be managed as deemed appropriate by the 
Investigator. If a subject develops thrombocytopenia CTCAE grade 3 or worse, study treatment 
should be interrupted for a maximum of 4 weeks. In some cases, management of 
thrombocytopenia may require platelet transfusions. Platelet transfusions should be done 
according to local hospital guidelines. 
 
Management of prolonged hematological toxicities while on study treatment 
 
If a subject develops prolonged hematological toxicity such as: 
 
• ≥2-week interruption/delay in study treatment due to CTC grade 3 or worse anemia 
and/or development of blood transfusion dependence 
• ≥2-week interruption/delay in study treatment due to CTC grade 3 or worse neutropenia 
(absolute neutrophil count < 1 x 109/L) 
• ≥2-week  interruption/delay  in  study  treatment  due  to  CTC  grade  3  or  worse 
thrombocytopenia (platelets <50 x 109/L) 
 
Weekly differential blood counts including reticulocytes (calculate reticulocyte index (RI), RI 
= reticulocyte count x hematocrit (Hct)/normal Hct; a value of 45 is usually used for normal 
Hct), and a peripheral blood smear should be performed. If any blood parameters remain 
clinically abnormal after 4 weeks of dose interruption, the subject should be referred to 
hematologist for further investigations. Bone marrow analysis and/or blood cytogenetic analysis 
should be considered at this stage according to standard hematological practice. 
 
Development of a confirmed MDS or other clonal blood disorder should be reported as an SAE. 
Study treatment should be discontinued if diagnosis of MDS is confirmed. 
 
The dose of olaparib must not be adjusted under any other circumstances unless the site 
Principal Investigator (PI) has provided a prior agreement. 
 
Management of neutropenia, leukopenia and thrombocytopenia 
 
Toxicity 
Study treatment dose adjustment 
 
CTCAE Grade 1-2               Investigator judgment to continue treatment or if dose interruption, this 
should be for a maximum of 4 weeks; appropriate supportive treatment 
and causality investigation 

43(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
Toxicity 
Study treatment dose adjustment 
 
CTCAE Grade 3-4 
Dose interruption until recovered to CTCAE gr 1 or better for a maximum 
of 4 weeks. If repeat CTCAE grade 3-4 occurrence, dose reduce olaparib 
to 250 mg twice daily as a first step and 200 mg twice daily as a second 
step 
 
 
 
Olaparib Dose reductions for study treatment 
 
Initial Dose 
Dose reduction 1 
Dose reduction 2 
300mg twice daily 
250mg twice daily 
200mg twice daily 
 
 
Management of new or worsening pulmonary symptoms 
 
If new or worsening pulmonary symptoms (eg, dyspnea) or radiological abnormality occurs, an 
interruption in olaparib dosing is recommended, and a diagnostic workup (including a high 
resolution CT scan) should be performed to exclude pneumonitis. Following investigation, if 
no evidence of abnormality is observed on CT imaging and symptoms resolve, then olaparib 
treatment can be restarted, if deemed appropriate by the Investigator. If significant pulmonary 
abnormalities are identified, these need to be discussed with the site PI. 
 
Management of nausea and vomiting 
 
Events of nausea and vomiting are known to be associated with olaparib treatment. In study 
D0810C00019, nausea was reported in 71% of the olaparib-treated subjects and 36% in the 
placebo-treated subjects; vomiting was reported in 34% of the olaparib-treated subjects and 14% 
in the placebo-treated subjects. These events are generally of mild to moderate (CTCAE grade 
1 or 2) severity, intermittent, and manageable on continued treatment. The first onset generally 
occurs in the first month of treatment, with the incidence of nausea and vomiting not showing 
an increase over the treatment cycles.   Both nausea and vomiting were reported to be 
intermittent for the majority of patients and can be managed by dose interruption, dose reduction 
and/or antiemetic therapy. 
 
No routine prophylactic anti-emetic treatment is required at the start of study treatment; 
however, subjects should receive appropriate anti-emetic treatment at the first onset of nausea 
or vomiting and as required thereafter, in accordance with local treatment practice guidelines. 
 
Renal Impairment 
 
If subsequent to study entry and while still on study therapy, a patient’s estimated CrCl falls 
below the threshold for study inclusion (≥51 ml/min), retesting should be performed promptly. 

44(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
A dose reduction is recommended for patients who develop moderate renal impairment 
(calculated creatinine clearance by Cockcroft-Gault equation of between 31 and 50 ml/min) for 
any reason during the course of the study: the dose of olaparib should be reduced to 200mg BD. 
 
Because the CrCl determination is only an estimate of renal function, in instances where the 
CrCl falls to between 31 and 50 mL/min, the investigator should use his or her discretion in 
determining whether a dose change or discontinuation of therapy is warranted. 
 
Olaparib has not been studied in patients with severe renal impairment (creatinine clearance 
≤ 30 ml/min) or end-stage renal disease; if patients develop severe impairment or end stage 
disease is it recommended that olaparib be discontinued. 
 
Hepatic Impairment 
 
If subsequent to study entry and while on study therapy, the patient develops hepatic impairment, 
the investigator should make every attempt to identify the underlying reason for the impairment. 
 
Olaparib can be administered to patients with mild or moderate hepatic impairment (Child-Pugh 
Classification A or B) with no dose adjustment. Olaparib has not been studied in patients with 
severe hepatic impairment and is NOT recommended for use in these patients. 
 
 
 
4.2.5    Durvalumab 
 
Durvalumab should be given at least 1 hour after the subject has taken their olaparib morning 
dose. Durvalumab will be administered as an IV infusion over 60 minutes (+/- 5 minutes) at a 
dose of 1500 mg every 28 days. 
 
Subjects allocated to the combination arm in the study will receive durvalumab via IV infusion 
at a dose of 1500 mg every 28 days in addition to olaparib tablets 300 mg bid. Treatment with 
durvalumab  will  commence  on  Day 1  of  each  28  day  cycles  and  will  continue  on  the 
recommended schedule until progression of disease, unacceptable toxicity, withdrawal of 
consent, or other reasons to discontinue treatment occur. Disease progression requires 
confirmation, treatment with durvalumab will continue between the initial assessment of 
progression and confirmation of progression. If progression is not confirmed, then the subject 
should continue on study treatment and on treatment assessments. 
 
4.2.6    Durvalumab: drug preparation 
 
The Investigational Products Supply section of AstraZeneca/MedImmune will supply 
durvalumab as a 500-mg vial solution for infusion after dilution. The solution contains 50 
mg/mL durvalumab, 26 mM histidine/histidine-hydrochloride, 275 mM trehalose dihydrate, 
and  0.02% (/volume)  polysorbate  80;  it  has  a  pH  of  6.0.  The  nominal  fill  volume  is 

45(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
10 mL.  Investigational product vials are stored at 2°C to 8°C (36°F to 46°F) and must not be 
frozen. Durvalumab must be used within the individually assigned expiry date on the label. 
 
For patients weighing >30 kg, a fixed dose of 1500 mg Q4W durvalumab (equivalent to 20 
mg/kg Q4W) (based on an average body WT of 75 kg) should be prepared. For subjects ≤30 kg 
body weight, dose is determined using body weight, calculating the stock volume of durvalumab 
to achieve the accurate dose according to Appendix D. If a patient weighs exactly 30 kg or less, 
then patient should receive weight-based dosing for durvalumab. 
 
The dose of durvalumab for administration must be prepared by the Investigator’s or site’s 
designated IP manager using aseptic technique.  Total time from needle puncture of the 
durvalumab vial to the start of administration should not exceed: 
 
• 
24 hours at 2°C to 8°C (36°F to 46°F) 
 
• 
4 hours at room temperature 
 
If in-use storage time exceeds these limits, a new dose must be prepared from new vials. Infusion 
solutions must be allowed to equilibrate to room temperature prior to commencement of 
administration. 
 
No incompatibilities between durvalumab and polyvinylchloride or polyolefin IV bags have 
been observed. Dose of 1500mg durvalumab for patients >30 kg will be administered using an 
IV bag containing 0.9% (w/v) saline with a final durvalumab concentration ranging from 1 to 
20 mg/mL, and delivered through an IV administration set with a 0.2- or 0.22-μm in-line filter. 
 
Remove a volume of IV solution from the IV bag equal to the calculated volume of durvalumab 
to be added to the IV bag prior to addition of durvalumab. Next, the volume of durvalumab (ie, 
30.0 mL for 1500 mg of durvalumab) is added to the IV bag such that final concentration is 
within 1 to 20 mg/mL (IV bag volumes 100 to 1000 mL).  Mix the bag by gently inverting to 
ensure homogeneity of the dose in the bag. 
 
4.2.7    Durvalumab: Doses and treatment regimens 
 
Patient weight at baseline should be used for dosing calculations in patients ≤30 kg unless there 
is a ≥10% change in weight.  Dosing day weight can be used for dosing calculations instead of 
baseline weight per institutional standard. 
 
For patients ≤30kg, calculate the dose volume of durvalumab and number of vials needed for 
the subject to achieve the accurate dose according to Appendix D. 
 
Durvalumab will be administered at room temperature (approximately 25°C) by controlled 
infusion via an infusion pump into a peripheral or central vein. Following preparation of 
durvalumab, the entire contents of the IV bag should be administered as an IV infusion over 
approximately 60 minutes (±5 minutes), using a 0.2, or 0.22-μm in-line filter. Less than 55 
minutes is considered a deviation. 

46(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
The IV line will be flushed with a volume of IV solution (0.9% [w/v] saline, (possibly using 
dextrose as diluent) equal to the priming volume of the infusion set used after the contents of 
the IV bag are fully administered, or complete the infusion according to institutional policy to 
ensure the full dose is administered and document if the line was not flushed. 
 
Standard infusion time is 1 hour.  However, if there are interruptions during infusion, the total 
allowed time should not exceed 8 hours at room temperature. The table below summarizes time 
allowances and temperatures. 
 
Table 3: Durvalumab hold and infusion times 
 
Maximum time from needle puncture to start 
of administration 
 
Maximum time for IV bag infusion, including 
interruptions 
4 hours at room temperature, 24 hours at 2°C to 
8°C 
 
8 hours at room temperature 
 
 
 
In the event that either preparation time or infusion time exceeds the time limits outlined above, a 
new dose must be prepared from new vials. Durvalumab does not contain preservatives, and any 
unused portion must be discarded. 
 
4.2.8    Durvalumab: monitoring of dose administration 
 
Subjects will be monitored before, during and after the infusion with assessment of vital signs 
at the times specified in the Schedule of Assessment. Subjects are monitored (pulse rate, blood 
pressure) every 30 minutes during the infusion period (including times where infusion rate is 
slowed or temporarily stopped). 
 
In the event of a ≤ Grade 2 infusion-related reaction, the infusion rate of study drug may be 
decreased by 50% or interrupted until resolution of the event (up to 4 hours) and re-initiated at 
50% of the initial rate until completion of the infusion.  For subjects with a ≤ Grade 2 
infusion-related reaction, subsequent infusions may be administered at 50% of the initial 
rate. Acetaminophen and/or an antihistamine (eg, diphenhydramine) or equivalent medications 
per institutional standard may be administered at the discretion of the investigator.  If the 
infusion-related reaction is Grade 3 or higher in severity, study drug will be discontinued. The 
standard infusion time is one hour, however if there are interruptions during infusion, the total 
allowed time from infusion start to completion of infusion should not exceed 8 hours at room 
temperature, with maximum total time at room temperature not exceeding 8 hours (otherwise 
requires new infusion preparation). 
 
As with any antibody, allergic reactions to dose administration are possible. Appropriate drugs 
and medical equipment to treat acute anaphylactic reactions must be immediately available, and 
study personnel must be trained to recognize and treat anaphylaxis.  The study site must have 
immediate access to emergency resuscitation teams and equipment in addition to the ability to 
admit subjects to an intensive care unit if necessary. Following preparation of durvalumab, the 

47(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
entire contents of the IV bag should be administered as an IV infusion over approximately 60 
minutes (+/- 5 minutes). 
 
4.2.9 Management of toxicity of durvalumab 
 
Durvalumab is an anti-PDL1 antibody that binds with high affinity and specificity to PD-L1 
and blocks its binding to PD-1 and CD-80; thus, it promotes anti-tumor immunity and tumor- 
cell killing. Potential risks based on this mechanism of action of durvalumab and related 
molecules include immune-mediated reactions such as enterocolitis, dermatitis, hepatotoxicity 
or hepatitis, endocrinopathy, neuropathy, and pneumonitis. This class of drug has a wide 
spectrum of immune-mediated reactions that have been considered inflammatory in nature and 
can affect any organ of the body. 
 
The following general guidance should be followed for management of toxicities. 
 
• Treat each of the toxicities with maximum supportive care (including holding the agent 
suspected of causing the toxicity where required). 
 
• If the symptoms promptly resolve with supportive care, consideration should be given 
to continuing the same dose of durvalumab along with appropriate continuing supportive 
care. If medically appropriate, dose modifications are permitted for durvalumab. 
 
• All dose modification should be documented with clear reasoning and documentation of 
the approach taken. 
 
Immune-related adverse events 
 
Based on the mechanism of action of durvalumab that leads to T-cell activation and 
proliferation, there is a possibility of observing immune-related AEs (irAEs) during the 
conduct of this study. Potential irAEs include immune-mediated enterocolitis, dermatitis, 
hepatitis, and endocrinopathies. Subjects should be monitored for signs and symptoms of 
irAEs. In the absence of an alternate etiology (eg, infection or PD) signs or symptoms of 
enterocolitis, dermatitis, hepatitis, and endocrinopathy should be considered to be immune- 
related. Following the first dose of durvalumab, subsequent administration of durvalumab 
can be modified based on toxicities observed and as described in Table 4. 
 
Table 4: Durvalumab dose modification due to toxicity 
 
See Appendix F for Toxicity Management Guidelines 
 
In addition to the dose modifications shown, it is recommended the management guidelines 
for irAEs are followed; these modifications are presented in Table 5 below: 
 
 
 
 
 
 
 

48(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
Table 5: Management of immune-related adverse events 
 
1 Subject evaluation to identify any alternative etiology 
2 In the absence of a clear alternative etiology, all events of an inflammatory nature should be 
considered to be immune-related 
3 Symptomatic and topic therapy should be considered for low-grade events 
4 Systemic corticosteroids should be considered for a persistent low-grade event or for a severe event 
5 More potent immunosuppressors should be considered for events not responding to systemic 
steroids. 
 
 
 
 
 
Pneumonitis 
 
Pneumonitis has been reported with use of anti-PDL1 / anti-PD-1 antibodies. Initial work up 
should include a high resolution CT scan to rule out infection and pulse oximetry. Additional 
assessments are to include pulmonary function tests and blood gases. Pulmonary consultation 
is recommended. For Grade 2 pneumonitis that does not resolve to ≤Grade 1 within 3 days 
of maximal   supportive   care   (including   steroids)   or   ≥Grade 3   pneumonitis,  permanently 
discontinue durvalumab. 
 
Infusion Reactions 
 
Subjects will be monitored during and after the infusion with assessment of vital signs (blood 
pressure [BP] and pulse) at the beginning of the infusion, every 30 minutes during the infusion, 
at  the  end  of  the  infusion,  and  at  30  and  60  minutes in  the  1-hour  observation  period 
post-infusion. If the infusion takes longer than 60 minutes, then BP and pulse measurements 
can be done more frequently if clinically indicated. 
 
In the event of a ≤Grade 2 infusion-related reaction, the infusion rate of durvalumab may be 
decreased by 50% or interrupted until resolution of the event (up to 4 hours) and re-initiated 
at 
50% of the initial rate until completion of the infusion. If, following 4 hours of interruption, 
there is a persistent Grade 2 toxicity despite the use of appropriate medications such as 
antihistamines or paracetamol, then study treatment should be discontinued. If, following 
4 hours of interruption, there is a decrease to Grade 1, then the drug may be re-introduced if 
it does not present an increased risk to the subject. 
 
Hypersensitivity reactions 
 
Hypersensitivity reactions, as well as infusion-related reactions, have been reported with 
anti-PDL1. As with any antibody, allergic reactions to dose administration are possible. 
Appropriate drug and medical equipment to treat acute anaphylactic reactions must be 
immediately available, and study personnel must be trained to recognize and treat anaphylaxis. 
The study site must have immediate access to emergency resuscitation teams and equipment in 
addition to the ability to admit subjects to an intensive care unit if necessary. 
 

49(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
Acute allergic reactions may occur, may be severe, and may results in death. Acute allergic 
reactions may include hypotension, dyspnea, cyanosis, respiratory failure, urticarial, pruritus, 
angioedema, hypotonia, urticarial, arthralgia, bronchospasm, wheeze, cough, dizziness, fatigue, 
headache, hypertension, myalgia, vomiting, and unresponsiveness. 
 
Hepatotoxicity 
Increased transaminases have been reported during treatment with anti--PDL1. 
Other AESIs observed with durvalumab include: 
• Colitis 
• Neuropathy / neuromuscular toxicity (i.e. events of encephalitis, peripheral motor and 
sensory neuropathies, Guillain-Barré, and myasthenia gravis) 
• Endocrinopathy (i.e. events of hypophysitis, adrenal insufficiency, and hyper- and 
hypothyroidism) 
• Dermatitis 
• Nephritis 
• Pancreatitis 
Further information on these risks (e.g. presenting symptoms) can be found in the current 
version of the durvalumab Investigator Brochure. 
 
4.2.10  Labeling 
 
Labels will be prepared in accordance with Good Manufacturing Practice (GMP) and local 
regulatory guidelines. The labels will fulfil GMP Annex 13 requirements for labelling. Label 
text will be translated into local language. 
 
Each bottle of olaparib will have an investigational product label permanently affixed to the 
outside stating that the material is for clinical trial/investigational use only and should be kept 
out of reach and sight of children. The label will include the dosing instructions to be reviewed 
at the time of dispensing. 
 
The label will include the following information: 
 
•           Blank lines for quantity of tablets to be taken 
 
•           Date dispensed 
 
• 
Instructions stating that the olaparib tablets should be taken at approximately the 
same time each morning and evening 
 
4.2.11   Storage 
 
All study drugs should be kept in a secure place under appropriate storage conditions. The 
investigational product label on the bottle and the Investigator Brochure specifies the 
appropriate storage. 
 
4.2.12  Treatment compliance 
 
The patient will be provided with a diary in which each participant must record date and time  
 
of each olaparib intake, reasons for any missed doses as well as any changes in dosing of study 
drug. Diaries will be provided to participants on Day 1 of cycle 1 and Day 1 (+/-2 days) of each 

50(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
subsequent cycle. Diaries will be collected as source documentation at the end of each dosing 
cycles and at the EOT visit to document study drug administration for evaluation of treatment 
compliance. If the participant does not return the diary, delegated staff must evaluate and 
document dosing compliance. 
 
The patient should return all boxes, bottles, blisters, and unused tablets of olaparib at the 
beginning of each new cycle (or at the end of each cycle).  Any remaining or returned tablets 
will be counted by the Investigator or a designated person from his/her team and recorded. 
 
If the patient does not bring the treatment dispensed at the previous visit back, the number of 
tablets taken will be estimated by the Investigator using the patient’s diary and by questioning 
the patient. The patient will need to return the study drug at the next visit. The eCRF drug 
accountability data entered by the study site personnel into the electronic data capture (EDC) 
will be the data used by analysis. 
 
Patients randomized to receiving durvalumab will receive treatment with durvalumab by study 
site staff at the study sites. Compliance will be assured by administration of the study treatment 
under the supervision of Investigator or his/her designee. 
 
4.2.13  Accountability 
 
Drug accountability will be the responsibility of the Investigator and/or the pharmacist.  The 
Investigator and/or the pharmacist of the center and/or a designated person from the study team 
must maintain an accurate record of receipt of all study drugs, including dates of receipt.  In 
addition, accurate records will be kept regarding when and how much study drug is dispensed 
and used by each patient in the study.  Reasons for departure from the expected dispensing 
regimen must also be recorded.  At the completion of the study, all study drugs will be 
reconciled and retained or destroyed according to local procedures and requirements. 
Destruction of unused therapeutic units will be performed according to standard modalities for 
that class of product.  Destruction of study drugs should occur for product returned after drug 
accountability or after expiration date, or after the last visit of the last treated patient at the latest. 

51(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
4.3 
Discontinuation of study treatment 
 
Subjects must be withdrawn from study treatment for the following reasons: 
 
• At  their  own  request  or  at  the  request  of  their  legally  acceptable  representative 
(withdrawal of consent for treatment). 
 
• At any time during study treatment and without giving reasons, a subject may decline to 
participate further. The subject will not suffer any disadvantage as a result. 
 
• If, in the Investigator's opinion, continuation of study treatment would be harmful to the 
subject's well-being. 
 
• Severe  allergic  reactions,  such  as  exfoliate  erythroderma,  anaphylaxis,  or  cardio 
vascular collapse. 
 
• Any   other   potential   adverse   reaction   deemed   sufficiently  serious   to   warrant 
discontinuation of treatment by either the Investigator or a designated associate(s). 
 
• Substantial non-compliance with study procedures. 
 
• Subjects with a beta human chorionic gonadotropin test consistent with pregnancy. 
Pregnancy will be reported along the same timelines as a serious adverse event (SAE) 
 
• Use of illicit drugs or other substances that may, in the opinion of the Investigator or a 
designated associate(s), have a reasonable chance of contributing to toxicity or otherwise 
confound the results. 
 
• Development of any intercurrent illness or situation that would, in the judgment of the 
Investigator, affect assessments of clinical status and study endpoints to a relevant 
degree. 
 
• Subjects should discontinue study treatment if confirmed disease progression occurs. If 
the treating physician feels that the subject will receive clinical benefit from continued 
study treatment despite progression, the subject may remain on study drug after 
consultation with the study PI. However, the subject will be considered as having 
progressive disease, as per the RECIST 1.1 criteria 
 
• Subject lost to follow-up 
 
• The date of the last dose of the second study drug is considered as the date of the end of 
the study treatment 
 
• Permanent discontinuation of a specific study drug should be declared by the site 
treating physicians 

52(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
In all cases, the reason for withdrawal from treatment must be recorded in the case report form 
(CRF) and in the subject’s medical 
records. 
 
4.4    Procedures for discontinuation of a subject from investigational product 
 
A subject whose treatment is permanently discontinued due to an adverse event or clinically 
significant laboratory value must be followed up as per institutional practice until resolution or 
stabilization of the event, whichever comes first. 
 
An end of treatment (EOT) visit should be conducted within 30 days of the last dose of the study 
drug or within 30 days of the decision to permanently discontinue the study drug. If the subject 
withdraws from the study at a scheduled visit, the EOT assessment can be performed on that 
day. (See section 4.5.3 for visit details) 
 
Any subject who has not progressed at the time of discontinuation of study treatment will 
continue to have tumor assessments performed every 8 weeks until disease progression, 
initiation of subsequent anticancer therapies or death, whichever comes first. 
 
Upon treatment discontinuation, subjects will be followed every 2 months for survival.  
Completion of the survival follow-up period will occur once the last subject in the 
Extension period discontinues study treatment, or the Extension period reaches one 
year of duration, whichever comes first.   
 
4.5    Collection of study variables 
 
The site Investigator will ensure the accuracy, completeness, and timeliness of the data recorded 
and of the provision of answers to data queries according to the Clinical Study Agreement. Data 
will be entered into the electronic case report form (eCRF) of a web-based data management 
system. Site personnel will be trained and responsible for entering data specified in the protocol 
into the eCRF according to the eCRF Instructions. Site personnel will provide their site local 
laboratory lab normal range values during the data management system set-up. When all data 
has been entered, reviewed, and source data verification completed; the site PI will be notified 
to sign the eCRF electronically. 
 
4.5.1    During olaparib or olaparib and durvalumab maintenance 
 
Cycle 1 Day 
1 
 
The following assessments will be done prior to administration of maintenance treatment: 
 
•       Physical examination 
 
•       ECOG performance status 
 
•       Vital signs (weight, temperature, blood pressure, respiration and pulse) 
 
•       Hematology 
 
•       Blood chemistry 
 

53(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
•       Liver function tests 
 • 
Thyroid function tests for combination arm only (thyroid stimulating hormone (TSH), 
free triiodothyronine (T3), and free thyroxine (T4))  
 
• 
Electrolytes 
 
• 
Correlative blood samples for translational studies 
 
• 
Assess adverse events (AE) 
 
• 
Record concomitant medication 
 
• 
Dispense olaparib or olaparib and administer durvalumab 
 
See Appendix G for additional laboratory requirements for Korean sites only. 
 
4.5.2 Subsequent visits 
 
Subsequent visits with study doctor should occur once every 28 days +/- 3 days for Cycle 2 
onward. More frequent visits are permitted if clinically indicated.  
While the  following assessments will continue to be performed, they will only be done for 
clinical purposes. These data will no longer be entered into the study database: 
 
• 
Physical examination 
 
• 
ECOG performance status 
 
• 
Vital signs (weight, temperature, blood pressure, respiration, pulse) 
 
• 
Hematology and Chemistry per tables 6 and 7 that follow: 
 
 
Table 6. Hematology Laboratory Tests 
 
 
 
Basophils 
Mean corpuscular volume 
 
Eosinophils 
Monocytes 
Hematocrit 
Neutrophils 
Hemoglobin 
Platelet count 
Lymphocytes 
Red blood cell count 
Mean corpuscular hemoglobin 
Total white cell count 
Mean corpuscular hemoglobin 
concentration 
 
 
 
 
 

54(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
 
 
Table 7. Clinical chemistry (Serum or Plasma) Laboratory Tests 
 
Albumin 
Glucose 
Alanine aminotransferase 
Thyroid stimulating hormone (TSH), free 
triiodothyronine (T3), and free thyroxine (T4)) 
(combination arm only) 
Magnesium 
Aspartate aminotransferase 
Potassium 
Bicarbonate 
Sodium 
Calcium 
Total bilirubina 
Chloride 
Total protein 
Creatinine 
Urea or blood urea nitrogen, depending on local 
practice 
a  If Total bilirubin is ≥2xULN (and no evidence of Gilbert’s syndrome) then fractionate into direct and indirect 
bilirubin 
 
See Appendix G for additional laboratory requirements for Korean sites only. 
 
4.5.3 End-of-study visit 
 
When it has been determined that a subject should be removed from treatment, she will be 
asked to return for a treatment termination visit, which should preferably occur within 30 days 
after her last administration of study drug. Wherever possible, this visit should also be 
undertaken by subjects who withdrew from the study prematurely. All subjects will be 
followed for a minimum of 30 days after the last dose of olaparib/durvalumab. 
 
If a subject is removed from the study due to drug-related adverse events, the subject will be 
followed until resolution of any drug-related AE occurring during the study or within 30 days 
of the last olaparib/durvalumab dose, or for 30 days, whichever is longer. In the presence of 
toxic effects, follow-up visits will be required every four weeks until all study-related 
toxicities have resolved to baseline (or <Grade 1 per CTCAE), have stabilized or are deemed 
irreversible. 
 
The following assessments will be made during the end of study visit: 
 
• Physical examination (including oral/tympanic temperature and body weight) 
 
• ECOG performance status 
 
• Vital signs (systolic and diastolic blood pressure, pulse rate). 

55(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
• Clinical laboratory profile (hematology, biochemistry and liver function test) per tables 
6 and 7 
 
• Radiological disease status assessment at Investigator’s discretion 
 
• 
Serious Adverse Events recording 
 
The only data to be entered into the eCRF from this visit will be the End of Treatment reason, 
radiological disease status assessment (if applicable), and Serious Adverse Event (if applicable).  
 
 
 
4.6 
Biological sampling procedures 
 
 
The volume of blood that will be drawn from each subject in this study is as follows: 
 
Table 8: Volume of blood to be drawn from each subject 
 
 
 
Assessment 
Sample 
volume (mL) 
Frequency of 
Sampling 
Total volume 
(mL) 
 
Safety 
Clinical 
chemistry 
 
3 
Once at the start of 
each cycle 
 
18 (for 6 cycles) 
 
Hematology 
3 
Once at the start of 
each cycle 
 
Biomarker 
30 
At predefined time 
points 
 
18 (for 6 cycles) 
 
 
120 (4 time 
points) 

56(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
Total 
36 
156 
 
 
 
 
 
4.6.1    Handling, storage and destruction of biological samples 
 
Serial blood samples will be collected from all patients. Please refer to Appendix A for schedule 
of assessment for sampling time points and table 9 for blood volume to be collected. All blood 
samples will be collected by either direct venipuncture or an indwelling central venous catheter. 
Complete instructions for blood sample processing, handling and shipment will be provided in 
the Laboratory Manual. 
 
4.6.2    Biomarker samples 
 
The specific description of collection, handling and shipment of these samples is described in a 
separate Correlative Science Lab Manual. 
 
Related to biomarker blood sample collection, specifically, the sites will collect blood at visits 
C1D1, D1 after each staging cycle (C3D1, C5D1, C7D1 etc), and EOT; please refer to the 
Schedule of Assessments (Appendix A) for further detail. 
 
While the goal of the biomarker assessments is to provide supportive data for the clinical study, 
there may be circumstances when a decision is made to stop collection or not perform or  
discontinue an analysis due to either practical or strategic reason (e.g. inadequate sample 
number, issues with quality of sample, issues with assays etc.). Depending on the results 
obtained during the study, sample collection and/or analysis may be omitted at the discretion of 
the study chair. If a decision is made by study chairs to stop collection of blood samples, 
notification will be provided to every investigator in writing. 
 
4.6.3    Withdrawal of informed consent for donated biomarker samples 
 
As collection of the biomarker samples is an integral part of the study, if the subject withdraws 
consent from the study, the study team will continue to retain and use all research results that 
have already been collected for the study evaluation. All biological samples that have already 
been collected may be retained and analysed at a later date or as required by local regulations. 
If a patient withdraws consent for the study, the investigator must make every effort to determine 
the primary reason for this decision and record this information. Subjects may decide to stop 
biomarker collection but continue on study. This does not constitute withdrawal of consent 
for the entire study. 
 
4.7    Follow-up procedures 
 
30-day safety follow-up 
 
All subjects will have safety evaluations for 30 days following the last dose of the study 
treatment. AEs will be assessed until 30 days following the last dose of olaparib and/or 
durvalumab. All concomitant medications given to a patient as a result of an SAE experienced 
during this period will be recorded. All cancer medications/therapies given to a subject ≤30 days 
after the last dose of olaparib/durvalumab must be recorded. Subjects lost to follow-up should 
be recorded as such. 
 

57(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
Disease progression follow-up 
 
Any subject who has not progressed at the time of discontinuation of study treatment will 
continue to have tumor assessments performed every 8 weeks (+/- 7 days) until disease 
progression, initiation of subsequent anticancer therapies or death, whichever comes first. 
 
Survival follow-up 
 
Upon completion of the 30-day safety follow-up or disease progression follow-up, all subjects 
except those who died, withdrew consent or were lost to follow-up will be followed for survival 
every 8 weeks (+/- 7 days) until death. Completion of the survival follow-up period will occur 
once the last subject in the Extension period discontinues study treatment, or the Extension 
period reaches one year of duration, whichever comes first.   
 
4.8    Efficacy 
 
The first disease evaluation for subjects following start of olaparib or olaparib in combination 
with durvalumab will occur at week 8 +/- 7 days. Subsequent to the first tumor evaluation, 
disease status and tumor response will be assessed per RECIST using standard CT/MRI scans 
in eight-week intervals (+/- 7 days) until disease progression as defined by RECIST 1.1 or as 
clinically indicated. 
 
For subjects who discontinue any of the study drug due to toxicity in the absence of confirmed 
objective progression, objective tumor assessments should be continued every 8 weeks (+/- 7 
days) for until confirmed objective disease progression. 
 
If study subject is on durvalumab, disease progression requires confirmation. The confirmatory 
scan should occur preferably at the next scheduled visit and no earlier than 4 weeks after the 
initial assessment of progressive disease (PD) in the absence of clinically significant 
deterioration. Treatment with olaparib and durvalumab will continue between the initial 
assessment of progression and confirmation for progression. Subjects with rapid tumor 
progression or with symptomatic progression that requires urgent medical intervention (eg, 
central nervous system metastasis, respiratory failure due to tumor compression, spinal cord 
compression) will not be eligible to continue to receive study drug. 
 
4.8.1    Efficacy outcome measures 
 
Only response evaluation per RECIST will be entered into eCRF for the Extension period.  
 
The primary efficacy outcome measure is as follows: 
 
PFS, defined as the time from randomization to the first occurrence of disease progression (as 
determined using RECIST v1.1 criteria and assessed by the Investigator) or death from any cause 
on study. Death on study is defined as death from any cause within 30 days of the last dose of 
study treatment regimen. Tumor progression will be assessed locally at each site by the 
investigators according to RECIST 1.1.   No independent review of tumor progression is planned. 
PFS with disease progression determined by iRECIST will also be examined in exploratory data 
analysis for the combination arm. The secondary efficacy outcome measures in all subjects are 
as follows: 
 
• OS (overall survival) defined as the time from randomization until death from any cause. 

58(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
• ORR (overall response rate) defined as the subjects achieving Complete Response or 
Partial Response as defined by RECIST 1.1. 
 
• CBR (clinical benefit rate) defined as subjects achieving Complete Response, Partial 
Response or Stable disease ≥ 24 weeks 
 
Methods of measurement 
 
The following definitions and criteria (from RECIST 1.1) should be used for the baseline 
evaluations of existing disease and for the ongoing evaluation of tumor responses. All 
measurements should be taken and recorded in metric notation, using a ruler or callipers. In the 
case of skin lesions, documentation by color photography and a measurement with a ruler to 
estimate the size of the lesion is recommended. 
 
• Measurable disease - the presence of at least one measurable lesion. 
 
• Measurable lesions – non-lymph node lesions that can be accurately measured in at 
least one dimension with LD 20 mm using conventional techniques or 10 mm with spiral 
CT scan, or 15mm for lymph nodes with spiral CT. 
 
• Non-measurable lesions - all other lesions ie, bone lesions, ascites, pleural/pericardial 
effusion, including lesions that do not meet the measureable criteria above. 
 
• Conventional CT should be performed with cuts of 10 mm or less in slice thickness 
contiguously. Spiral CT should be performed using a 5-mm contiguous reconstruction 
algorithm. 
 
All imaging methods should be performed according to institutional standards with each subject 
having consistency of methods beginning from baseline through the course of the study. 
 
Table 9: Response criteria 
 
Evaluation of target lesions 
Complete 
Response (CR): 
Disappearance of all target lesions 
Partial Response 
(PR): 
At least 30% decrease in the sum of the LD of target lesions, taking as reference the 
baseline sum LD 
Progressive 
Disease (PD): 
At least a 20% increase in the sum of the LD of target lesions, taking as reference the 
nadir (smallest sum) LD recorded since the treatment started or the appearance of one or 
more new lesions 
Stable Disease 
(SD) 
Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, 
taking as reference the smallest sum LD since the treatment started 
Evaluation of non-target lesions 
Complete 
Response (CR): 
Disappearance of all target lesions 
Stable Disease 
(SD) 
Persistence of one or more non-target lesion(s) 

59(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
Progressive 
Disease (PD): 
Appearance of one or more new lesions and/or unequivocal progression of existing non- 
target lesions 
 
 
Evaluation of Best Overall Response 
 
The best overall response is the best response recorded from the start of the treatment until 
disease progression and is determined as per Table 10 below. 

60(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
Table 10: Definition of best overall response as per RECIST criteria 
 
Target lesions 
Non-Target lesions 
Evaluation of New lesions 
Overall response 
CR 
CR 
No 
CR 
CR 
SD 
No 
PR 
PR 
Non-PD 
No 
PR 
SD 
Non-PD 
No 
SD 
PD 
Any 
Yes or No 
PD 
Any 
PD 
Yes or No 
PD 
Any 
Any 
Yes 
PD 
 
 
To be considered a response, CR or PR must persist for a minimum of 4 weeks. If, at the time 
of tumor response evaluation, either a PR or CR is observed, the same radiographic study should 
be repeated 4 weeks later for confirmation of response. After this confirmatory study, subjects 
should return to the schedule of evaluations as previously described. 
 
5     SAFETY 
 
The Principal Investigator is responsible for ensuring that all staff involved in the study is 
familiar with the content of this section. 
 
5.1     Definition of adverse events 
 
An adverse event (AE) is the development of an undesirable medical condition or the 
deterioration of a pre-existing medical condition following or during exposure to a 
pharmaceutical product, whether or not considered causally related to the product. An 
undesirable medical condition can be a symptom (eg, nausea, chest pain), sign (eg, tachycardia, 
enlarged liver) or the abnormal results of an investigation (eg, laboratory findings, 
electrocardiogram). In clinical studies, an AE can include an undesirable medical condition 
occurring at any time even if no study treatment has been administered. 
 
The term AE is used to include both serious and non-serious AEs. The Common Terminology 
Criteria for Adverse Events (CTCAE) version 4.03 will be used to report AEs for this study. 
 
5.2    Definitions of serious adverse event 
 
A serious adverse event is an AE occurring during any study phase that fulfils one or more of 
the following criteria: 
 
•           Results in death not related to breast cancer disease progression 
 
•           Is immediately life-threatening 
 
•           Requires in-patient hospitalization or prolongation of existing hospitalization 
 
•           Results in persistent or significant disability or incapacity 

61(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
•           Is a congenital abnormality or birth defect 
 
• 
Is an important medical event that may jeopardize the subject or may require 
medical intervention to prevent one of the outcomes listed above. 
 
The causality of SAEs (their relationship to all study treatment/procedures) will be assessed 
by the Investigator(s) and documented or reported on the SAE eCRF page. 
 
5.3    Definition of adverse events of special interest (AESI) 
 
An adverse event of special interest (AESI) is one of scientific and medical interest specific to 
understanding of the Investigational Product and may require close monitoring and rapid 
communication by the investigator to the sponsor. An AESI may be serious or non-serious. The 
rapid reporting of AESIs allows ongoing surveillance of these events in order to characterize 
and understand them in association with the use of this investigational product. 
 
AESIs for durvalumab include but are not limited to events with a potential inflammatory or 
immune-mediated mechanism and which may require more frequent monitoring and/or 
interventions such as steroids, immunosuppressants and/or hormone replacement therapy. These 
AESIs are being closely monitored in clinical studies with durvalumab monotherapy and 
combination therapy. An immune-related adverse event (irAE) is defined as an adverse event 
that is associated with drug exposure and is consistent with an immune-mediated mechanism of 
action and where there is no clear alternate aetiology. Serologic, immunologic, and histologic 
(biopsy) data, as appropriate, should be used to support an irAE diagnosis. Appropriate efforts 
should be made to rule out neoplastic, infectious, metabolic, toxin, or other etiologic causes of 
the irAE. 
 
Only AESIs meeting serious criteria will be reported during the Extension period.  
 
 
If the Investigator has any questions in regards to an adverse event (AE) being an 
irAE, the Investigator should promptly contact the Study Chair. 
 
Criteria for Hy’s Law (FDA Guidance 2009) 
 
• The drug causes hepatocellular injury, generally shown by a higher incidence of 3-fold 
or greater elevations above the ULN of ALT or AST than the (non-hepatotoxic) control 
drug or placebo 
 
• Among   trial   subjects   showing   such   aminotransferase   elevations,  often   with 
aminotransferases much greater than 3 x ULN, one or more also show elevation of serum 
total bilirubin to >2 x ULN, without initial findings of cholestasis (elevated serum 
alkaline phosphatase). 
 
• No other reason can be found to explain the combination of increased aminotransferases 
and total bilirubin, such as viral hepatitis A, B, or C; pre-existing or acute liver disease; 
or another drug capable of causing the observed injury. 
 
5.4    Recording of adverse events 
 
For the Extension period, only SAEs will be reported in eCRFs. Non-serious AEs will be 

62(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
managed according to the site’s clinical practice and the toxicity management guidelines set 
forth in this protocol, but will not be reported in eCRFs. 
Information about all SAEs, whether volunteered by the subject, discovered by Investigator 
questioning, or detected through physical examination, laboratory test, or other means, will be 
collected and recorded and followed as appropriate. 
 
All SAEs, whether or not deemed drug-related, must be reported within IBM-CD (eCOS) 
by the site Investigator or qualified designee within 1 business day of first becoming 
aware of the event. 
 
Questions about SAE reporting can be referred to DCRI Safety Surveillance at 1-919- 
668-8624, or at 1-866-668-7799 within North America. 
 
If the IBM-CD system is temporarily unavailable, the event, including the Investigator- 
determined causality to study drug, should be reported via a paper back-up SAE form to 
DCRI Safety Surveillance. Upon return of the availability of IBM-CD system, the SAE 
information must be entered into IBM-CD. 
 
The following variables will be collected in the eCRF 
during the Extension period for each SAE: 
 
•           SAE (verbatim per CTCAE) 
 
•           The date when the SAE started and stopped 
 
•           Changes in NCI CTCAE grade and the maximum CTC grade attained 
 
  
•           Investigator causality rating against the Investigational Product (yes or no) 
/combination drug (yes/no) 
 
•           Action taken with regard to investigational product /combination agent 
 
•           Outcome 
 
 
•           Date AE met criteria for serious AE 
 
• 
Reason AE is defined as serious (fatal or life threatening, results in persistent or 
significant disability/incapacity, constitutes a congenital anomaly/birth defect, is 
medically significant, requires inpatient hospitalization or prolongation of existing 
hospitalization). 
 
•           Date of hospitalization 
 
•           Date of discharge 
 
•           Probable cause of death 
 
•           Date of death 
 

63(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
•           Autopsy performed 
 
•           Description of AE 
 
•           Causality assessment in relation to Study procedure(s) 
 
•           Causality assessment in relation to other medication 
 
•           Causality assessment in relation to additional study drug 
 
It is important to distinguish between serious and severe AEs. Severity is a measure of intensity, 
whereas seriousness is defined by the criteria in Section 5.2. An AE of severe intensity need not 
necessarily be considered serious. For example, nausea that persists for several hours may be 
considered severe nausea, but not a SAE. On the other hand, a stroke that results in only a 
limited degree of disability may be considered a mild stroke but would be a SAE. 
 
5.4.1    Time period for collection of adverse events and serious adverse events 
 
All SAEs will be collected during the extension period through 30 days after the last dose of 
either drug or until the initiation of an alternative anticancer therapy. Please refer to the 
Schedule of Assessments in Appendix A. 
 
5.5    Follow-up of unresolved serious adverse events 
 
All SAEs should be treated appropriately. Such treatment may include changes in study drug 
treatment, including possible interruption or discontinuation, starting or stopping concomitant 
treatments, changes in the frequency or nature of assessments, hospitalization, or any other 
medically required intervention. Once an SAE is detected, it should be followed until its 
resolution, and assessment should be made at each visit (or more frequently, if necessary) of 
any changes in severity, the suspected relationship to the study drug, the interventions required 
to treat it, and the outcome. 
 
5.6    Adverse events based on signs and symptoms 
 
When collecting SAEs, the recording of diagnoses is preferred (when possible) to recording a list 
of signs and symptoms. However, if a diagnosis is known and there are other signs or symptoms 
that are not generally part of the diagnosis, the diagnosis and each sign or symptom will be 
recorded separately. 
 
5.7    Adverse events based on examinations and tests 
 
Deterioration as compared to baseline in protocol-mandated laboratory values, for vital signs 
should only be reported if they fulfil any of the SAE criteria or are the reason for discontinuation 
of treatment with the investigational product. 
 
If deterioration in a laboratory value/vital sign is associated with clinical signs and symptoms, 
the sign or symptom will be reported as the event  and the associated laboratory result/vital sign 
will be considered as additional information. Wherever possible the reporting Investigator uses 
the clinical, rather than the laboratory term (eg, anemia versus low hemoglobin value).  
 
Deterioration of a laboratory value, which is unequivocally due to disease progression, should 
not be reported as an SAE 
 

64(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
Cases where a subject shows an AST or ALT ≥3xULN and total bilirubin ≥2xULN may need 
to be reported as SAEs, please refer to Section 5.3 (AESI definition) for further instructions. 
 
5.8    Disease progression 
 
Disease progression can be considered as a worsening of a subject’s condition attributable to 
the disease for which the investigational product is being studied. It may be an increase in the 
severity of the disease under study and/or increases in the symptoms of the disease. SAEs due 
to progression will be reported and classified as unrelated to treatment. 
 
5.9    New cancers 
 
The development of a new primary cancer should be regarded as an SAE since this event will 
generally meet at least one of the serious criteria (see Section 5.2). New primary cancers are 
those that are not the primary reason for the administration of the study treatment and have 
developed after the inclusion of the subject into the study. These do not include metastases of 
the original cancer. Symptoms of metastasis or the metastasis itself should not be reported as 
an AE/SAE, as they are considered to be disease progression. 
 
5.10  Lack of efficacy 
 
When there is deterioration in the condition for which the study treatment(s) is being used, 
mTNBC, there may be uncertainty as to whether this is lack of efficacy or an AE. In such cases, 
unless the Sponsor or the reporting physician considers that the study treatment contributed to 
the deterioration of the condition, or local regulations state to the contrary, the deterioration 
should be considered to be a lack of efficacy and not an AE. 
 
5.11  Deaths 
 
All deaths that occur during the study, or within the protocol-defined 30-day post-study 
follow-up period after the administration of the last dose of study treatment, must be reported 
as follows: 
 
• 
Death that is clearly the result of disease progression should be documented in the 
eCRF but should not be reported as an SAE. 
 
• 
Where death is not due (or not clearly due) to progression of the disease under study, 
the main or primary event causing the death must be documented in the eCRF as a 
SAE within 1 business day (see Section 5.2 for further details). The report should 
contain a comment regarding the co-involvement of progression of disease, if 
appropriate, and should assign main and contributory causes of death. 
 
• 
Deaths with an unknown cause should always be reported as a SAE. A post mortem 
maybe helpful in the assessment of the cause of death, and if performed a copy of the 
post-mortem results should be included within the eCRF. 
 
5.12  Other events requiring reporting 
 
5.12.1  Pregnancy 
 
If a patient becomes pregnant during the course of the study, the IPs should be discontinued 
immediately. 
 

65(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
Pregnancy itself is not regarded as an AE unless there is a suspicion that the IP under study may 
have interfered with the effectiveness of a contraceptive medication. Congenital abnormalities 
or birth defects and spontaneous miscarriages should be reported and handled as SAEs. Elective 
abortions without complications should not be handled as AEs. The outcome of all pregnancies 
(spontaneous miscarriage, elective termination, ectopic pregnancy, normal birth, or congenital 
abnormality) should be followed up and documented even if the patient was discontinued from 
the study. 
 
If any pregnancy occurs in the course of the study, then the Investigator or other site personnel 
should inform the sponsor or their designated representatives within 1 business day, ie, 
immediately, but no later than 1 business day of when he or she becomes aware of it. 
 
The same timelines apply when outcome information is available. 
 
 
5.12.2  Reporting of serious adverse events 
 
SAEs are reported with the eCRF database within 1 business day of the investigator’s knowledge 
of the event. 
 
* The investigative site must also indicate, the causality of events in relation to all study 
medications and if the SAE is related to disease progression, as determined by the site Principal 
Investigator. 
 
 
5.12.3 Translational study 
 
Biopsies and tissue specimen 
 
At time of enrollment, all archival or fresh tissue obtained will be banked. This will be a 
requirement for participation in the study. Where possible, formalin-fixed paraffin embedded 
(FFPE) blocks are preferred. If blocks are unavailable, thirty unstained and unbaked 5-μm slides 
from each subject (minimum of 10 slides for pre-treatment biopsy/archival tissue required) 
should be processed as close to batch shipment date as possible. Post-treatment biopsy is 
encouraged but optional. All tissue will be banked at the site until the batch shipment date near 
full enrolment of the trial. Each sample will be labelled with Subject ID code and the required 
number of slides retained / shipped to the relevant research laboratories.   All blood, tissue 
samples and buccal swabs will be processed centrally by the Duke BioRepository & Precision 
Pathology Center (BRPC). Shipping back to the Duke BioRepository & Precision Pathology 
Center (BRPC) will be arranged and communicated to the sites nearing the end of enrollment. 
Please see lab manual for further details. 
 
All study subjects will have a buccal swab for germline DNA collected during screening; these 
will banked at study sites until the end of the study. 
 
Immunohistochemical HRD assay 
 
Banked tumor samples will be profiled based on protein expression using multiplexed 
microscopy. The multiplexing ability of the Opal-Vectra system will be used to study different 
antibody combinations relevant to homologous recombination for all samples obtained in this 

66(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
study. 
 
Whole exome sequencing (WES) 
 
DNA samples will be obtained from the tumor samples and from the buccal DNA swabs that 
will be obtained during screening. PCR-based exon sequencing will be performed using standard 
techniques. Genetic variants will be characterized as missense, nonsense, and frameshift, and 
then will be narrowed by retaining only somatic rare variants and homozygous mutations. Wald 
testing will initially be used to define relationships between gene alterations and response to 
therapy. 
 
We also have a very large set of profiled primary and metastatic TNBC samples (both 
carboplatin sensitive and insensitive) that will serve as a comparator set for the samples in this 
proposal (Blackwell, SABCS, 2013). We will be able to use this established and well- 
characterized set for quality control and gene mutation comparison. 
 
Immune profiling 
 
Immune profiling will be done using standard immunohistochemistry techniques. The following 
immune markers will be stained and quantitated using an experienced breast pathologist who 
will quantitate staining in tumor and in the stroma. The following markers will be assessed 
initially: 
 
1.   Quantitative TILs using H and E stained slide21 
 
2.   CD4 
 
3.   CD8 
 
4.   FoxP3 (SP97) 
 
5.   Anti PDL-1 (E1L3N) 
 
Modifications to the immune markers may be made depending on emerging evidence. 
 
 
6    ETHICAL AND REGULATORY REQUIREMENTS 
 
6.1    Ethical conduct of the study 
 
This trial will be conducted in compliance with this protocol, Good Clinical Practice guidelines 
(eg, ICH E6: Good Clinical Practice or Singapore Guideline for Good Clinical Practice 
[SGGCP]), and applicable national and local regulatory requirements. 
 
The site Principal Investigator shall ensure that personnel involved in the conduct of this study 
are qualified by education, training, and experience to perform their respective tasks. The site 
Principal Investigator has ultimate responsibility for trial conduct at the site. 
 
The study will be performed in accordance with ethical principles that have their origin in the 
Declaration of Helsinki and are consistent with ICH/Good Clinical Practice, and applicable 
regulatory requirements. 
 

67(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
6.2    Subject data protection 
 
Subjects will be assigned unique code numbers and will not be identified by name. Subject 
confidentiality is held strictly in trust by the participating Investigators, their staff, the 
sponsor(s), and their agents. This confidentiality extends to genetic and biological sample tests, 
in addition to the clinical information relating to participating subjects. 
 
The sponsor will not provide individual genotype results to subjects, any insurance company, 
any employer, their family members, general physician or any other third party, unless required 
to do so by law. 
 
Extra precautions are taken to preserve confidentiality and prevent genetic data being linked to 
the identity of the subject. In exceptional circumstances, however, certain study staff might see 
both the genetic data and the personal identifiers of a subject. For example, in the case of a 
medical emergency, the medical monitor or an Investigator might know a subject’s identity and 
also have access to his or her genetic data. Also, Regulatory authorities may require access to 
the relevant files, though the subject’s medical information and the genetic files would remain 
physically separate. 
 
The study protocol, documentation, data, and all other information generated will be held in 
strict confidence. No information concerning the study or the data will be released to any 
unauthorized third party without prior written approval of the sponsor. 
 
6.3    Ethics and regulatory review 
 
Before study initiation, the Investigator must have written and dated approval/favorable opinion 
from the IRB/IEC for the protocol, consent form, subject recruitment materials/process (eg, 
advertisements), and any other written information to be provided to prospective subjects. The 
Investigator should also provide the IRB/IEC with a copy of the product labelling information 
to be provided to prospective subjects, along with any updates. 
 
The Investigator should provide the IRB/IEC with reports, updates, and other information (eg, 
expedited safety reports, amendments, and administrative letters) according to local and national 
regulatory requirements or institution procedures. 
 
6.4    Informed consent 
 
Investigators must ensure that subjects are clearly and fully informed about the purpose, 
potential risks, and other critical issues regarding this clinical study for which they are 
volunteering to participate. 
 
Before any study procedures are performed, potential subjects will have the outline of the study 
described to them, and they will be given a written informed consent document to read. If they 
consent to participate in the study, they will indicate that consent by signing and dating the 
informed consent document in the presence of study personnel. Any subject who signs the 
consent form will be considered a “screened” subject. 
 
6.5    Changes to the protocol and informed consent form 
 
Should amendments to the protocol and/or informed consent document be required, the 
amendments will be written by the sponsor and provided to the Investigator for submission to 

68(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
their IRB/IEC. 
 
6.6    Protocol deviations 
 
Protocol deviations (noncompliance with the clinical trial protocol, Good Clinical Practice 
(GCP), Manual of Procedures or requirements) will be noted in Site Monitoring reports. Of note, 
noncompliance may be either on the part of the participant, the site Investigator, or the study 
site staff. Sites are expected to develop and implement corrective actions promptly. 
 
It is the responsibility of the site to use continuous vigilance to identify and report deviations. 
All deviations must be promptly reported to the sponsor or their designee. 
 
All deviations from the protocol must be addressed in study subject source documents. Protocol 
deviations must be reported to the local IRB/IEC per local guidelines. The site PI/study staff is 
responsible for knowing and adhering to their IRB/IEC requirements. 
 
6.7    Publication policy 
 
Dissemination of preliminary information can adversely affect the objectivity of study data. For 
this reason, Investigators will not be allowed to perform subset analyses at any point before the 
conclusion of the study, and any data, other than safety data, cannot be used for publication or 
reporting outside of this study until the study is completed or discontinued by the 
sponsor/investigator. 
 
 
7    STATISTICAL METHODS AND SAMPLE SIZE DETERMINATION 
 
7.1    Statistical analyses and determination of sample size 
 
Based upon current standard of care,30 the median PFS (mPFS) in this population is estimated 
to be approximately 2 months, and a clinically relevant improvement with either of the proposed 
maintenance treatments would be to an mPFS of 4 months. In both arms of the study, it is 
proposed to test a null hypothesis of an mPFS of 2 months against an alternative hypothesis of 
an mPFS of 4 months. To test this hypothesis, assuming an exponential PFS distribution, use of 
an exponential MLE test, a two-sided significance level of 5% and a power of 90%, 25 subjects 
are required per arm. To allow for a drop-out rate of approximately 20%, the sample size per 
arm will be inflated to 30 subjects, for a total of 60 subjects. 
 
Comparison between the two treatment arms will be performed as an exploratory analysis. 
 
The number of subjects that will agree to participate in the genetic research is unknown. It is 
therefore not possible to establish whether sufficient data will be collected to allow a formal 
statistical evaluation or whether only descriptive statistics will be generated. A statistical 
analysis plan will be prepared where appropriate. 
 
7.2    Safety data review committee 
 
Accruing vital status, progression, and safety data will be reviewed by the committee comprising 
the Dora Study Chair, Study Co-Chair and Correlative Science Chair; one of the Study Chairs 
will serve as the bi-monthly committee meeting leader.  The DCRI statistician will serve as the 
meeting secretary and will provide agreed-upon statistical reports in advance of the committee 
meeting. The Safety Data Review Committee’s primary goal is to determine if there is a clear 

69(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
early difference between the Arms A and B in terms of safety, efficacy, or risk-benefit. The 
Safety Data Review Committee may invite opinions from the study site investigators, 
intermittently, and will consider stopping either one, or both, arms if the safety profile is 
unacceptable. The committee will meet together and review rates of deaths, SAEs, and 
progressions approximately every 2 months until all subjects have been accrued. A written 
committee charter will provide guidance regarding meeting conduct; the DCRI statistician and 
the meeting Chair will jointly prepare summary minutes from each meeting and circulate for 
review by the committee members. 
 
 
8    LIST OF REFERENCES 
 
1. 
Boyle 
P: 
Triple-negative 
breast 
cancer: 
epidemiological 
considerations 
and 
recommendations. [Internet]. Ann Oncol 23 Suppl 6:vi7–12, 2012. 
 
2. Dent R, Trudeau M, Pritchard KI, et al: Triple-negative breast cancer: clinical features and 
patterns of recurrence. Clin Cancer Res 13:4429–4434, 2007. 
 
3. Gennari A, Stockler M, Puntoni M, et al: Duration of chemotherapy for metastatic breast 
cancer : a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol 
29:2144–2149, 2011 
 
4. Ledermann J, Harter P, Gourley C, et al: Olaparib maintenance therapy in patients with 
platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of 
outcomes by BRCA status in a randomized phase 2 trial. Lancet Oncol 15:852–861, 2014. 
 
5. Ledermann J, Harter P, Gourley C, et al: Olaparib maintenance therapy in platinum-sensitive 
relapsed ovarian cancer. [Internet]. N Engl J Med 366:1382–1392, 2012. 
 
6. Atchley DP, Albarracin CT, Lopez A, et al: Clinical and pathologic characteristics of patients 
with BRCA-positive and BRCA-negative breast cancer J Clin Oncol 26:4282–4288, 2008. 
 
7. Anders CK, Carey LA: Biology, metastatic patterns, and treatment of patients with triple- 
negative breast cancer. Clin Breast Cancer 9 Suppl 2:S73–81, 2009. 
 
8. Sorlie T, Tibshirani R, Parker J, et al: Repeated observation of breast tumor subtypes in 
independent gene expression data sets. Proc Natl Acad Sci U S A 100:8418–8423, 2003. 
 
9. Loi S, Sirtaine N, Piette F, et al: Prognostic and predictive value of tumor-infiltrating 
lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast 
cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-beased 
chemotherapy: BIG 02-98. J Clin Oncol 31:860–867, 2013. 
 
10. Adams S, Gray RJ, Demaria S, et al: Prognostic value of tumor-infiltrating lymphocytes in 
triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: 
ECOG 2197 and ECOG 1199. J Clin Oncol 32:2959–2966, 2014. 
 
11. Denkert C, Loibl S, Noske A, et al: Tumor-associated lymphocytes as an independent 
predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28:105–113, 
2010. 

70(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
12. Loi S, Sirtaine N, Piette F, et al: Prognostic and predictive value of tumor-infiltrating 
lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast 
cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based 
chemotherapy: BIG 02-98. J Clin Oncol 31:860–867, 2013. 
 
13. Schalper KA, Velcheti V, Carvajal D, et al: In situ tumor PD-L1 mRNA expression is 
associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res 
20:2773–82, 2014. 
 
14. Mittendorf  EA, Philips AV, Meric-Bernstam F, et al: PD-L1 expression in triple-negative 
breast cancer. Cancer Immunol Res 2:361–370, 2014. 
 
15. Evers B, Schut E, van der Burg E, et al. A high-throughput pharmaceutical screen identifies 
compounds with specific toxicity against BRCA2-deficient tumors. Clin Cancer Res 16:99– 
108; 2010. 
 
16. Farmer H, McCabe N, Lord CJ, et al: Targeting the DNA repair defect in BRCA mutant 
cells as a therapeutic strategy. Nature 434:917–921; 2005. 
 
17. Bryant HE, Schultz N, Thomas HD, et al: Specific killing of BRCA2-deficient tumors with 
inhibitors of poly(ADP-ribose) polymerase. Nature 434;913–917; 2005. 
 
18. McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by 
homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer 
Res 66:8109–8115; 2006. 
 
19.  Menear  KA,  Adcock  C,  Boulter  R,  et  al.  4-[3-(4-cyclopropanecarbonylpiperazine- 
1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP- 
ribose) polymerase-1. J Med Chem 51:6581–6591; 2008. 
 
20. Kim G, Ison G, McKee AE, et al. FDA approval summary: olaparib monotherapy in patients 
with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more 
lines of chemotherapy. Clin Cancer Res 21:4257–4261; 2015. 
 
21. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and 
patterns of recurrence. Clin Cancer Res 13:4429–4434; 2007. 
 
22. Lee E, McKean-Cowdin R, Ma H, et al. Characteristics of triple-negative breast cancer in 
patients with a BRCA1 mutation: results from a population-based study of young women. J Clin 
Oncol 29:4373–4380; 2011. 
 
23. Lehmann BD1, Bauer JA, Chen X, et al. Identification of human triple-negative breast 
cancer subtypes  and preclinical models for  selection of  targeted therapies. J  Clin Invest 
12:2750–2767; 2011. 
 
24. Denkert C, von Minckwitz G, Brase JC, et al. Tumor-infiltrating lymphocytes and response 
to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor 
receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol 33:983–991; 2015. 
 

71(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
25. Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating 
lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast 
cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based 
chemotherapy: BIG 02-98. J Clin Oncol 31:860–867; 2013. 
 
26. Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in patients with advanced triple- 
negative breast cancer: Phase Ib KEYNOTE-012 Study. J Clin Oncol 34:2460–2467. 2016 [E- 
published ahead of print] 
 
27. Nanda R, Chow LQ, Dees EC, et al. A phase Ib study of pembrolizumab (MK-3475) in 
patients with advanced triple-negative breast cancer. SABCS 2014; Abstract S1–09. 
 
28. Emens LA, Braiteh FS, Cassier P, et al. Inhibition of PD-L1 by MPDL3280A leads to 
clinical activity in patients with metastatic triple-negative breast cancer (TNBC). Presented at 
the American Association for Cancer Research Annual Meeting; April 18–22, 2015; 
Philadelphia. Abstract 2859. 
 
29. Ng CM, Lum BL, Gimenez V, et al. Rationale for fixed dosing of pertuzumab in cancer 
patients based on population pharmacokinetic analysis. Pharm Res. 2006;23(6):1275–84. 
 
 
 
30. Wang DD, Zhang S, Zhao H, et al. Fixed dosing versus body size based dosing of 
monoclonal antibodies in adult clinical trials. J Clin Pharmacol. 2009;49(9):1012–24. 
 
31. Zhang S, Shi R, Li C, et al. Fixed dosing versus body size-based dosing of therapeutic 
peptides and proteins in adults. J Clin Pharmacol. 2012;52(1):18–28. 
 
32. Narwal R, Roskos LK, Robbie GJ et al. Population Pharmacokinetics of Sifalimumab, an 
Investigational Anti-Interferonalpha Monoclonal Antibody, in Systemic Lupus Erythematosus. 
Clin Pharmacokinet. 2013 52:1017–1027. 
 
33. Lee JM, Dos Santos Zimmer A, Lipkowitz S, et al.; Phase I study of the PD-L1 inhibitor, 
durvalumab (MEDI4736; D) in combination with a PARP inhibitor, olaparib (O) or a VEGFR 
inhibitor, cediranib (C) in women's cancers (NCT02484404). J Clin Oncol 34, 2016 (suppl; abstr 
3015) 
 
34. O’Shaughnessy J, Schwartzberg L, Danso MA, et al. Phase III study of iniparib plus 
gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic 
triple-negative breast cancer. J Clin Oncol 32:3840–3847, 2014. 
 
35. Tutt A, Tovey H, Cheang MC et al. Carboplatin in BRCA1.2 mutated and triple-negative 
breast cancer BRCAness subgroups: the TNT Trial. Nature Med 24(5):628-637, 2018. 
 
36. Seymour L, Bogaerts J, Perrone A, et al on behalf of the RECIST working group. iRECIST: 
guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017; 
18(3):e143-152. 

72(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
9 APPENDICES 
 
Appendix A : Schedule of Assessments 
 
Extension period – please refer to sections 4.5.2 and 4.5.3 for data to be entered in eCRF.  
 
SCHEDULE OF ASSESSMENTS 
Procedures 
Screeningp 
Cycle 1 
(q28) 
Cycle 2 
(q28) 
onwards 
End of 
treatment 
Follow-up 
Within 14 
days 
D1 
D1 (+/- 3 
days) 
Within 30 
days 
Every 8 
weeks 
(+/- 7 days) 
Informed consent 
X 
Inclusion/exclusion 
criteria check 
X 
Demographics 
X 
Past medical history 
including past cancer 
chemotherapy, 
radiotherapy and 
surgery 
X 
Archival tumor tissue 
sample 
Xb 
Tumor assessment (CT 
or MRI)c 
X 
Xd 
Xd 
Complete physical 
examination 
X 
X 
X 
X 
Weight (with height at 
screening) 
X 
X 
X 
 
 
 
 
 
 

73(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
Vital signse 
X 
Xe 
Xe 
X 
AE and toxicities 
X 
X 
X 
Xf 
Concomitant 
medications 
X 
X 
X 
X 
ECOG performance 
status 
X 
X 
X 
X 
Hematologyg 
X 
Xn 
X 
X 
Chemistry and 
electrolyteh 
X 
Xo 
X 
X 
Liver panel 
(ALT/AST/Bilirubin)i 
X 
Xn 
X 
X 
GFR assessmentj 
X 
Xn 
X 
X 
Pregnancy testk 
X 
Buccal Swab for DNA 
analysis 
X 
Biomarker blood testsl 
X 
X [after 
staging, at 
alternating 
Cycles 
3,5,7, etc] 
X 
Optional tumor biopsym 
Xl 
Xm 
If CR/PR/SD: 
Randomization 
X 
Olaparib 
300 mg BID daily 
If randomized to 
combination arm: 
Durvalumab IV 1500 
mg 
X 
X 
Survival assessmentn 
Xn 
NOTE: Results of standard-of-care tests or examinations performed prior to obtaining informed consent but within the screening 
window (Day-14 to Day -1) may be used for the study. Investigations, such as CT or MRI scans that have been performed as 
part of routine clinical practice to assess response to platinum, can be used as part of the screening process if performed within 
28 days of first dose of study treatment. Screening assessments are to be performed within 14 days preceding cycle 1 day 1 
unless otherwise noted. Except for cycle 1 day 1, all other study visits and assessments during the treatment period should be 
performed within +/- 3 days of the scheduled date. Study assessments may be delayed or moved ahead of the window to 
accommodate holidays, vacations and unforeseen delays. All assessments and procedures to be performed pre-dose unless 
otherwise specified. 
 
a  The end of treatment visit should occur approximately 30 days after the last administration of olaparib or durvalumab 

74(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
whichever is discontinued last, or until initiation of another therapeutic regimen. 
 
b Archival tissue (either formalin fixed paraffin embedded tumor specimens or a minimum of 10 unstained paraffin slides) must 
be available prior to entry into the study. In the absence of archival tissue, fresh tissue biopsy samples, excluding cytology and 
fine needle aspiration specimens are acceptable. 
 
c Tumor assessments performed according to RECIST version 1.1 The method used for a patient (CT or MRI) must be the same 
throughout the study. 
 
d Tumor assessment performed every 8 weeks starting on Days 21-28 of Cycle 2 and every 8 weeks (+/- 7 days) thereafter until 
documented disease progression. The results should be reviewed prior to dosing at the next cycle; tumor assessments should be 
performed < =7 days prior to continuation of study treatment on Day 1 of the subsequent cycle. 
 
e Includes heart rate, systolic and diastolic blood pressure whilst in a seated position, and temperature. On durvalumab dosing 
days, recorded prior to dosing and at the end of the infusion. 
 
f Patients with unresolved adverse events or serious adverse events will be followed until the event is resolved or stabilized, the 
patient is lost to follow-up or it has been determined that the study treatment or participation is not the cause of the event. 
 
g Includes RBC count, WBC count, WBC differential count (neutrophils, bands, lymphocytes, eosinophils, basophils, monocytes 
and other cells), absolute neutrophil count, hemoglobin, hematocrit and platelet count. 
 
h  Includes sodium, potassium, chloride, bicarbonate urea, creatinine, calcium, phosphorus, magnesium, thyroid stimulating 
hormone (combination arm only), free triiodothyronine (T3) (combination arm only) and free thyroxine (T4) (combination arm 
only). See Appendix G for additional required tests for Korean sites only. 
 
i Includes total bilirubin, total protein, albumin, AST, ALT and alkaline phosphatase. 
 
j As calculated by the Cockcroft-Gault formula. 
 
k For women of childbearing potential (including those who have had a tubal ligation). For all other women, documentation 
must be present in medical history confirming the patients is not of childbearing potential. 
 
l Biomarker blood specimens will be collected at visit C1D1, D1 after each staging cycle (C3D1, C5D1, C7D1 etc), and End of 
Treatment (EOT). 
 
m Tumor biopsy collection is optional for study participation if archival tissue is available. For patients who consent for tumor 
biopsy, this will be collected prior to treatment, and/or during interval of clinical response, at the time of progression and/or at 
the end of the study. 
 
n Information about survival and subsequent anti-cancer therapies will be collected via telephone calls, patient medical records 
and or clinic visits approximately every 8 weeks until death, loss to follow-up, or study termination unless the patient requests to 
be withdrawn from follow-up; this request must be documented and signed by the investigator. 
 
o Where laboratory investigations have not been performed within the 7-day period prior to starting treatment, they must be 
repeated on day 1 of cycle. 
 
P ECG is required at screening for Korean sites only. See Appendix G. 

75(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
Appendix B : Known Strong in Vivo Inhibitors or Inducers of CYP3A 
 
Strong Inhibitors of CYP3Aa 
Strong Inducers of CYP3Ae 
Boceprevir 
carbamazepinef 
clarithromycinb 
phenytoinf 
conivaptinb 
rifampinf 
grapefruit juicec 
St John's wortf 
indinavir 
itraconazoleb 
ketoconazoleb 
lopinavir/ritonavirb (combination drug) 
mibefradild 
nefazodone 
nelfinavir 
posaconazole 
ritonavirb 
saquinavir 
telaprevir 
telithromycin 
voriconazole 
Source: 
FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Web link Accessed 21 January 
2015: 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm 
#inVivo 
Note: The list of drugs in these tables is not exhaustive. Any questions about drugs not on this list should be addressed to the 
Study Chair of the protocol. 
a. A strong inhibitor for CYP3A is defined as an inhibitor that increases the AUC of a substrate for CYP3A by ≥ 5-fold. 
b. In vivo inhibitor of P-glycoprotein. 
c. The effect of grapefruit juice varies widely among brands and is concentration-, dose-, and preparation-dependent. Studies 
have shown that it can be classified as a “strong CYP3A inhibitor” when a certain preparation was used (eg, high dose, 
double strength) or as a “moderate CYP3A inhibitor” when another preparation was used (eg, low dose, single strength). 
d. Withdrawn from the United States market because of safety reasons. 
e. A strong inducer for CYP3A is defined as an inducer that results in ≥ 80% decrease in the AUC of a 
substrate for CYP3A. 
f. In vivo inducer of P-glycoprotein. 

76(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
Appendix C : Adverse Event Assessment of Causality 
 
Is there a reasonable possibility that the event may have been caused by study 
drugs? No  
 Yes  
 
 
The descriptions provided below will help guide the principal investigator in making 
the decision to choose either “yes” or “no”: 
 
No = There is no reasonable possibility that the event may have been caused by 
study drugs. 
 
The adverse event: 
• may be judged to be due to extraneous causes such as disease or 
environment or toxic factors 
• may be judged to be due to the subject’s clinical state or other therapy being 
administered 
• is not biologically plausible 
• does not reappear or worsen when study drug is re-administered 
• does not follow a temporal sequence from administration of study drug 
 
Yes = There is a reasonable possibility that the event may have been caused by 
study drugs. 
 
The adverse event: 
• follows a temporal sequence from administration of study drug 
• is a known response to the study drug based on clinical or preclinical data 
• could not be explained by the known characteristics of the subject’s clinical 
state, environmental or toxic factors, or other therapy administered to the 
subject 
• disappears or decreases upon cessation or reduction of dose of study drug 
• reappears or worsens when study drug is re-administered 

77(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
Appendix D : Under 30 kg Total Body Weight Durvalumab Dose calculation 
Dose Calculations ONLY for subjects 30kg body weight and under.  ALL subjects over 30kg 
total body weight are given fixed dosing of 1500mg every 4 weeks (see section 1.5.2) 
 
1. Ordered dose: 20 mg/kg 
 
 
2. Subject weight: X kg 
 
 
3. Dose for subject: Y mg = 20 (mg/kg) × X (kg) 
 
 
4. Dose to be added into infusion bag: 
 
 
Dose (mL) = Y mg/50 (mg/mL) where 50 mg/mL is durvalumab nominal concentration. 
 
 
The corresponding volume of durvalumab should be rounded to the nearest tenth mL (0.1 mL). 
Dose adjustments for each cycle are only needed for greater than 10% change in weight. 
 
5. The theoretical number of vials required for dose preparation is the next greatest whole 
number of vials from the following formula: 
 
Number of vials = Dose (mL)/10.0 (mL/vial) 
 
Example for 30kg subject dosing at 20mg/kg every 4 weeks: 
 
1. Ordered dose: 20 mg/kg every 4 weeks 
 
 
2. Subject weight: 30 kg 
 
 
3. Dose for subject: 600 mg = 20 (mg/kg) × 30 (kg) 
 
 
4. Dose to be added into infusion bag: Dose (mL) = 600 mg/50 (mg/mL) = 12.0 mL 
 
 
5. The theoretical number of vials required for dose preparation: 
Number of vials = 12.0 (mL)/10.0 (mL/vial) = 2 vials 
(provided by Astra Zeneca) 

78(80) 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
Appendix E : Assessment of Possible Drug Induced Liver Injury 
 
The following assessments are to be reported in the clinical database, utilizing Comment 
Form as necessary for additional information. 
 
• Subject’s age, sex, weight, and height 
 
• Signs and symptoms related to hepatotoxicity: type and timing to exposure 
 
• Relationship of exposure duration and dose to the development of the liver injury 
 
• Pertinent medical history • Concomitant drugs with dates and doses • Pertinent physical 
exam findings 
 
• Test results (e.g., laboratory data, biopsy data and reports, with dates and normal ranges) 
 
• Time course of serum enzyme and bilirubin elevations (consider tabular and/or graphical 
display of serial laboratory data) 
 
• A summary of all available clinical information including, if known: 
 
− Prior or current history of ethanol use 
 
− Presence of 
risk factors 
for NASH (e.g., obesity, diabetes, 
marked 
hypertriglyceridemia) 16 Contains Nonbinding Recommendations 
 
− Evidence for pre- or co-existing viral hepatitis, or other forms of liver disease, prestudy 
AT values, if available 
 
− Symptoms and clinical course including follow-up to resolution − Special studies (i.e., 
ultrasound, radiologic examinations, liver biopsy results) 
 
− Presence or absence of possible confounders, including concomitant illness, use of 
concomitant drugs that are known hepatotoxins, such as acetaminophen 
 
• Treatment provided 
 
• Dechallenge and rechallenge results, if done 
 
• Outcomes and follow-up information 
 
• The site should also supply redacted copies of available hospital discharge summaries, 
pathology and autopsy reports 

Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
79(80) 
 
 
 
 
 
 
Appendix F : Toxicity Management Guidelines Durvalumab  
 
These guidelines are now provided to sites as a separate document.  
 

 
80(80) 
 
Phase II Multicenter Study of Durvalumab and Olaparib in platinum tReated Advanced triple negative breast cancer 
V 6.0 
 
 
 
 
 
Appendix G : Additional required tests (Korean sites ONLY) 
 
 
 
4.1.2 Screening Procedures 
 
• 12 lead resting ECG 
• Amylase, Lipase, GGT (gamma glutamyl transferase), Urinalysis 
 
4.5.1 During olaparib or olaparib and durvalumab maintenance 
 
• Amylase, Lipase 
• As clinically indicated: GGT, Urinalysis 
 
4.5.2 Subsequent visits (and Table 7. Clinical chemistry Serum or Plasma Laboratory Tests) 
 
• Amylase, Lipase 
• As clinically indicated: GGT, Urinalysis 
 
 
 
 
Urinalysis Testsa 
 
Bilirubin 
Blood 
Glucose 
Ketones 
pH 
Protein 
Specific gravity 
 
Colour and appearance 
 
a Microscopy should be used as appropriate to investigate white blood cells and use the high 
power field for red blood cells